

The Silent Man Speaks



Study shows evidence of a duodenal ulcer with associated spasm.

His duodenal ulcer registers unspoken anxiety

He "seems" so willing to please—this silent man. When asked, he works unreasonable hours without complaint. He is imposed upon by family, relatives, friends—without question. Such a nice, quiet man—outside. But inside, flare-ups of abdominal distress betray his exasperation as well as his unspoken anxiety. In fact, his duodenal ulcer becomes his "spokesman."

The need to treat G.I. hypermotility and hypersecretion

As his overanxiety has been building, so also has hypermotility and hypersecretion. Increased gastric secretions and hypermotility, of course, are conditions that adversely affect the healing process. This is where Librax® provides dual action—may be highly useful.

The dual nature of Librax

Only Librax combines, in one capsule, the antianxiety action of Librium® (chlordiazepoxide HCl) and the antisecretory action of Quarzan® (clidinium

Before prescribing, please consult complete product information, a summary of which follows.

Indications: Symptomatic relief of hypersecretion, hypermotility and anxiety and tension states associated with organic or functional gastrointestinal disorders; and as adjunctive therapy in the management of peptic ulcer, gastritis, duodenitis, irritable bowel syndrome, spastic colitis, and mild ulcerative colitis.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. As with all CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chlordiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and after discontinuation of barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age require that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, in elderly and debilitated, limit dosage to small overactive or confusion (not more than two capsules per day initially; increase gradually as needed and tolerated). With other psychotropics seems indicated, carefully consider interacting drugs such as MAO inhibitors and phenothiazines, hepatic function. Paradoxical reactions (e.g., excitement, patients). Employ usual precautions in treatment of anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary.

Very rare effects of blood coagulation have been reported.

Caution: relationship has not been established clinically.

Adverse Reactions: No side effects or manifestations not seen with either compound alone have been reported with Librax.

When chlordiazepoxide hydrochloride is used alone, drowsiness, ataxia and confusion may occur, especially in the elderly.

bearing age require that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, in elderly and debilitated, limit dosage to small overactive or confusion (not more than two capsules per day initially; increase gradually as needed and tolerated).

With other psychotropics seems indicated, carefully consider interacting drugs such as MAO inhibitors and phenothiazines, hepatic function. Paradoxical reactions (e.g., excitement, patients). Employ usual precautions in treatment of anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary.

Very rare effects of blood coagulation have been reported.

Caution: relationship has not been established clinically.

Adverse Reactions: No side effects or manifestations not seen with either compound alone have been reported with Librax.

When chlordiazepoxide hydrochloride is used alone, drowsiness, ataxia and confusion may occur, especially in the elderly.

adjunctive Librax®

Each capsule contains 5 mg chlordiazepoxide HCl and 2.5 mg clidinium Br.

and debilitated. These are reversible in most instances by proper dosage adjustment, but are also occasionally observed at the lower dosage ranges. In a few instances, no side effects are reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms. Increased and decreased libido—all infrequent and generally controlled with dosage reduction; changes in EEG patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally with chlordiazepoxide hydrochloride, making periodic blood counts and liver function tests advisable during prolonged therapy. Adverse effects reported with Librax are typical of anticholinergic agents, i.e., dryness of mouth, blurring of vision, urinary hesitancy and constipation. Constipation has occurred most often when Librax therapy is combined with other spasmolytics and/or low residue diets.

ROCHE
Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, N.J. 07110

Medical Tribune

©1973, Medical Tribune, Inc.

Vol. 14, No. 39

world news of medicine and its practice—fast, accurate, complete

Wednesday, October 17, 1973

Study of Chronic Use of Marijuana Demonstrates No Chromosome Breaks, Brain Damage, or Untoward Effects

Medical Tribune Report

NEW YORK—A double-blind clinical study of the effects of marijuana in a sample of a population long habituated to its use has yielded no evidence of significant physiologic or psychoneurologic differences between smokers and a control group of nonsmokers.

The study, which was commissioned by the U.S. Department of Health, Education, and Welfare to obtain controlled clinical evidence, so far lacking, about the effects of chronic—as opposed to acute—use of cannabis, was carried out on the Island of Jamaica by the Research Institute for the Study of Man, New York, in collaboration with the Faculty of Medicine, University of West Indies, Kingston.

The results of this investigation appear to lay at rest many common beliefs about the deleterious effects of marijuana—beliefs based on laboratory observations (or anecdotes) of acute effects in haphazardly collected groups of study subjects, without regard for idiosyncratic physiologic differences or behavioral or sociologic background.

The project was begun in June, 1970, with a broad and intense 18-month anthropologic study to define typical marijuana smokers in representative Jamaican communities, and the final report, *Effects of Chronic Smoking of Cannabis in Jamaica*, embracing physiologic field studies

Continued on page 34



Analysis of the movements of farmers working cooperatively suggests that muscular coordination is impaired after smoking marijuana. They work harder and more happily, they say, but they get less done—an acute effect found in this study.

Vitamin E Fails To Ease Angina In Toronto Trial

Medical Tribune World Service

INSIDE THIS ISSUE

- 4,000 colonoscopies, no major complications.

pg. 5

- Wistar study implicates virus in multiple sclerosis. pg. 11.
- Sterilization suggested in women with severe diabetes. pg. 29.
- Electromagnets quicken nerve regeneration. pg. 32.

Complete Index, pg. 2

Continued on page 36

A Cure You Wouldn't Think Of: Noise for a Mouse Hangover

Medical Tribune Report

EAST LANSING, Mich.—There may be people who have had big heads who think it shouldn't happen to a mouse, but exposing the animal to intermittent noise during alcohol withdrawal will hasten recovery from symptoms.

Animal stimulation enhances the development of inhibitory mechanisms, with resulting physiologic adaptation, two investigators from the University of Georgia School of Pharmacy reported here.

In experiments conducted by C. Philip Conner III and W. B. Iturral, Ph.D., mice of the CF-1 strain were made alcohol-dependent and then subjected to a "noise



test" to assess the severity of the acute withdrawal reaction.

Such alcohol-dependent mice are susceptible to sound-induced seizure for hours after they go on the wagon. Mr. Conner said in describing study findings to the fall meeting of the American Society for Pharmacology and Experimental Therapeutics held at Michigan State University.

Specifically, an initial startle response is followed by a short blind run, the mouse falls on its side in clonic convulsions, and it may show tonic flexion and extension.

This reaction—which the investigators term "identical in all respects" to audio-

Continued on page 7

Long Flat EEG, Patient on Respirator Is Dead

Medical Tribune World Service

BARCELONA, SPAIN—If, in an unconscious patient who cannot breathe on his own, the brain registers no EEG activity, the likelihood is that he is irreversibly dead, said Dr. Benjamin Boshes, chairman of the Department of Neurology, Northwestern University Medical School, Chicago.

"A patient coming in totally unresponsive, requiring a respirator to sustain life, with flat EEG, stands a very high chance of being dead within 24 to 48 hours, provided there is no sedative drug intoxication," Dr. Boshes said.

"He will be equally dead if that decision is made 12 hours after the first flat EEG or after six hours. The question has been raised as to the likelihood of his being irreversibly dead if the decision is made after one hour, but much more data are needed to make this sure."

"The safest procedure at this point in



WIN AN ORIGINAL DALI PRINT
100 Weekly Winners
For 8 Weeks
See Page 3 for Details

No Evidence That DDT Increases Liver Cancer

Medical Tribune World Service

AUCKLAND, NEW ZEALAND—There is no evidence that exposure of large numbers of persons to DDT for more than 30 years, and of the whole world population for nearly 20 years, has produced any part of the increase in liver cancer that was once feared, according to the Australian Nobelist Sir Macfarlane Burnet.

Giving this year's Sir Douglas Robb lecture at Auckland University, he also said that apart from an apparent rise in leukemia—probably due to better diagnosis—and the massive rise in lung cancer, there has been no significant increase in any of the major forms of cancer since the beginning of the century.

The belief that small doses of radiation could cause leukemia was based on the assumption that the cell damage was irreversible, he said, but this has now been disproved. Consequently, there is no justification for ascribing any significant proportion of leukemia or any other cancer to natural ionizing radiation, he said.

Recent evidence indicates that there is a threshold below which radiation has no effect, Sir Macfarlane declared.

First Acupuncture Baby Delivered in Australia In 'Impressive' Procedure

Medical Tribune World Service

SYDNEY, AUSTRALIA—This country's first acupuncture baby, an 8-pound 12-ounce girl, was delivered uneventfully here at Mona Vale Hospital September 9 in a procedure that Dr. Harvey Turk, an obstetrician who was standing by in case of difficulties, found "very impressive."

The delivery was by Dr. Rainer, a lay acupuncturist who has been practicing for five years since receiving training in Hong Kong.

"It was incredible," Dr. Turk commented. "Whenever there were contractions, Mr. Rainer twiddled his needles and the patient was out of pain."

A leading Sydney gynecologist, Prof. Derrick Llewellyn-Jones, welcomed the news of the event.

"I think acupuncture deliveries will become more common in Australia now," he said. "I think this will be a good thing. It is an excellent way of delivering a baby and has many advantages over drugs."

Low Insulin Secretion Related To Defect in Beta-Cell Signal

Medical Tribune World Service

BRUSSELS—Low insulin secretion seems to be common to prediabetes and diabetes and to be the result of defective initiation or transmission of a glucose insulin-releasing signal to the beta cell, the eighth Diabetes Congress was told here.

Presenting his findings in the Solomon A. Berson memorial lecture, Dr. Rolf Luft, of Karolinska Hospital, Stockholm, said this view carries at least two important implications:

- Further characterization of the cellular mechanisms in the defect of beta-cell receptor sensitivity or affinity for glucose may facilitate the development of pharmacologic agents.
- The possibility of preventing the metabolic consequences of insulin deficiency becomes a more realistic aim.

Dr. Luft said his team's work points to a cybernetic system governing glucose-stimulated insulin release. The glucose acts on a beta-cell membrane receptor to produce an insulinogenic signal, he said, but just how this signal is transmitted is not yet clear. Cyclic AMP is probably operative at some point in the process, he said.

Dutch MDs Raise Fees

Medical Tribune World Service

THE HAGUE—Consultation fees chargeable by general practitioners to private patients have been raised to 13.75 guilders (U.S. \$5.08) for office visits and 20.5 (U.S. \$7.60) for house calls.

His own view, he explained, is that cancer is a side effect of the evolutionary process and a means of regulating the life span of the species.

Even in the case of lung cancer, all the figures available indicate that age is just as important as cigarettes in determining the incidence of the disease, he stated.

A characteristic of old age is that it is a time when a considerable number of dis-

eases become conspicuous, and cancer is the most important of them, Sir Macfarlane observed.

Almost all the common cancers increase steadily with age, as do strokes and heart attacks, he noted, adding that there is also evidence that the immune responses are heavily implicated in aging.

He believes that the thymus is the key organ in the process of aging.

Hospital Features Hotel Facilities



Genauer Clinic, which opened recently near Geneva, Switzerland, combines some features of both hotel and hospital. The idea, borrowed from Japan, is that a patient who requires extended care may have a number of the family stay with him. Facilities include an indoor pool and rooms with twin beds.

news index

CLINICAL NEWS NOTE: "As alcohol is released from the stomach it is readily absorbed from the gut; this alcohol is then metabolized in the liver, producing acetate, which circulates back to the stomach, inhibiting gastric emptying. Thus, alcohol absorption is controlled by its own metabolism." (Dr. C. D. Eskelson; see page 38.)

Medicine: pgs. 1, 2, 4, 5, 6, 11, 14, 23, 38, 39

Increased liver cancer due to DDT exposure is not supported by any evidence, according to an Australian Nobelist

Systemic mycoses infections—their relative importance and specific characteristics—are discussed by this week's guest consultant

Multiple sclerosis may be triggered by a virus that also figures in the disease process itself

Lyophilized BCG administered orally is sometimes effective in stimulating tumor immune response

Carcinoembryonic antigen, useful for diagnosing colorectal cancer, lacks specificity for screening

Ob/Gyn: pgs. 2, 29

Severely diabetic women should be advised by their physicians to avoid pregnancy, particularly when vascular disorders exist

Pediatrics: pgs. 5, 29, 39

Parents' role in minimal brain dysfunction was among the subjects discussed in a course on MBD in children

Research: pgs. 1, 2, 11, 28, 32, 38

Electromagnetic exposure appears to accelerate the regeneration of peripheral nerves in laboratory studies

Sodium acetate slows alcohol absorption in laboratory animals and may lead to a new approach to alcoholism and gluttony in man

Surgery: pgs. 2, 5, 14, 32

Colonoscopy is reportedly unlimited in diagnosing lesions throughout the length of the colon

On this basis he has concluded that this is perhaps a new virus that differs from known papovaviruses.

A male patient aged 46 admitted to the Neurology Department of the Kyushu University Hospital in July, 1970, was diagnosed as having a case of PML.


When the patient died in September, 1970, no formalin was used, but the body was stored in a refrigeration chamber, Dr. Amako said. The Pathology Department removed half the patient's brain and carried out a virologic examination.

This revealed scattered pathologic changes in the white matter, according to Dr. Amako, and when these were examined by electron microscope, virus particles about 40 millimicrons in size were discovered inside the nuclei of the glial cells. He said that the virus, in view of its negative staining and particle microstructure, belonged to the Papovavirus genus.

Since it is impossible to identify the species of a virus simply from its morphology, Dr. Amako said the investigators effected a microagglutination reaction under the electron microscope of the virus removed

MEDICAL TRIBUNE is published each Wednesday except on Jan. 31, May 30, Aug. 29, Sept. 26, Oct. 31, by Medical Tribune, Inc., 880 Third Ave., New York, N.Y. 10022. Controlled circulation postage paid at Farmington, Conn. \$7.50. Subscription \$12.50. Students, \$7.50.

WIN AN ORIGINAL DALI PRINT



"Greed and Extravagance"

NO OBLIGATION. SIMPLY COMPLETE THIS COUPON AND MAIL TODAY.

800 Winners 100 each week 1 Grand Prize an original oil portrait

a full face oil portrait
of yourself or any member of your family.
PLUS...an all expense paid trip to
NEW YORK CITY for the sittings
...or the artist will come to your home.

OFFICIAL RULES NO OBLIGATION NO PURCHASE REQUIRED

1. Enter as many times as you like!! Simply complete the self-addressed coupon and mail today—or enter by sending your name, address, and telephone number to: MEDICAL TRIBUNE SWEEPSTAKES C/O ROBERT SCOTT INTERMAR, INC., 880 MADISON AVENUE, NEW YORK, N.Y. 10022.

2. Entrants eligible to win only 2 weekly drawings...However, all entrants are eligible for the Grand Prize Drawing.

3. Winners receive a portrait oil painting. Grand Prize Drawing winners will be given a choice of oil painting or a portrait oil painting.

4. All weekly winners selected by random drawing from all entries received each week will be given a portrait oil painting.

5. Sweepstakes runs from September 10-October 31, 1973. All entries must be postmarked by November 17, 1973, and received by December 1, 1973.

6. Winners will be notified by mail.

7. Sweepstakes open to all persons, except employees and their families of Medical Tribune, Inc., its subsidiaries and affiliated companies, and their affiliated services.

8. Individual winners are responsible for taxes levied with regard to this sweepstakes.

9. Program judged and supervised by Robert Scott Intermar, N.Y., N.Y., an independent judging organization.

6

NAME _____

ADDRESS _____

CITY _____ STATE _____ ZIP _____

AGE: UNDER 40 40-65 OVER 65

PRACTICE: GENERAL SPECIALTY _____

APPROXIMATE NUMBER OF PATIENTS SEEN WEEKLY

LESS THAN 50 50-100 MORE THAN 100

APPROXIMATE % OF PRACTICE TIME SPENT IN HOSPITAL

0% 25% 50% OVER 50%

ROCHE announces
new

BACTRIMTM

Each tablet contains 80 mg trimethoprim and 400 mg sulfamethoxazole.

a new type of antibacterial
for a two-pronged attack
against chronic urinary
tract infections due to
susceptible organisms

Bactrim is highly effective in the treatment of these infections—primarily pyelonephritis, pyelitis and cystitis—when due to susceptible organisms. This efficacy is related to the unique mode of action against bacteria (see illustration). This action that, in effect, makes Bactrim a new type of antibacterial.

Bactrim interrupts the life cycle of susceptible bacteria

Unique mode of action interrupts the life cycle at two important points, thereby impeding the production of nucleic acids and proteins essential to these bacteria. These consecutive interruptions occur because sulfamethoxazole and trimethoprim resemble naturally existing substrates. By competitive replacement of these substrates, they inhibit further synthesis.


Prescribing considerations

Clinical Limitations: Currently, the increasing frequency of resistant organisms is a limitation of the usefulness of all antibacterial agents, especially in the treatment of chronic and recurrent urinary tract infections. Not recommended for children under twelve.

Contraindications: Hypersensitivity to trimethoprim or sulfonamides. Pregnancy and during the nursing period.

Warnings and Precautions: Both sulfamethoxazole and trimethoprim have been reported to interfere with hematopoiesis. Complete blood counts should be done frequently. If a significant reduction in the count of any formed blood element is noted, Bactrim should be discontinued. Bactrim should be given with caution to patients with impaired renal or hepatic function, possible folate deficiency, severe allergy or bronchial asthma. Maintain adequate fluid intake. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with impaired renal function.

Adverse Effects: Among the most common side effects are nausea, vomiting, rash, leukopenia and elevations in SGOT and creatinine.



ROCHE

Excellent clinical response in chronic urinary tract infections even with obstructive complications

A multiclinic, double-blind study* of response to a ten-day course of therapy in 471† patients with chronic urinary tract infections demonstrated the superiority of Bactrim. On the 10th day after initiation of therapy, 91.7% (of 168 patients) showed significant

bacteriological response to Bactrim, compared with 81.2% (of 144 patients) to trimethoprim and 64.5% (of 155 patients) to sulfamethoxazole. More than half of these patients had obstructive complications.

Excellent response maintained

Bactrim proved equally impressive in maintaining this bacteriological response. In the above study, after a ten-day course of therapy with Bactrim, 68.4% of patients with chronic urinary tract infections maintained response for up to 42 consecutive days, compared with

59.7% with trimethoprim and 44.4% with sulfamethoxazole. These results are particularly noteworthy considering the number of patients with obstructive complications—cases regarded as being notoriously difficult to treat.


*Data on file, Hoffmann-La Roche Inc., Nutley, N.J. 07110

†4 patients not available for evaluation at day 10.

new **BACTRIMTM**
Each tablet contains 80 mg trimethoprim and 400 mg sulfamethoxazole.
for chronic urinary tract infections

Before prescribing, please see complete product information on following page.

Rx
Bactrim
Tablets #40
Sig: Ti B.I.D.



- New type of antibacterial
- Unique dual mode of action
- Effective against susceptible urinary tract invaders: usually *E. coli*, *Klebsiella-Enterobacter*, *P. mirabilis*, and, less frequently, indole-positive proteus species
- No loading dose
- B.I.D. dosage
- Usual therapy: 10-14 days
- Excellent response in chronic urinary tract infections, primarily pyelonephritis, pyelitis and cystitis, due to susceptible organisms
- Impressive response in cases with urinary obstruction

Complete Product Information:

Description: Bactrim is a synthetic antibacterial combination product, available in scored light-green tablets, each containing 80 mg trimethoprim and 400 mg sulfamethoxazole.

Trimethoprim is 2,4-dimino-5-(3,4,5-trimethoxybenzyl) pyrimidine. It is a white to light yellow, odorless, bitter compound with a molecular weight of 290.3.

Sulfamethoxazole is *N*-(5-methyl-3-isoxazolyl) sulfanilamide. It is almost white in color, odorless, tasteless compound with a molecular weight of 253.28.

Action: *Microbiology*: Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. Thus, Bactrim blocks two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria.

In vitro studies have shown that bacterial resistance develops more slowly with Bactrim than with trimethoprim or sulfamethoxazole alone.

In vitro serial dilution tests have shown that the spectrum of antibacterial activity of Bactrim includes the common urinary tract pathogens with the exception of *Pseudomonas aeruginosa*. The following organisms are usually susceptible: *Escherichia coli*, *Klebsiella-Enterobacter*, *Proteus mirabilis* and indole-positive proteus species.

Representative Minimum Inhibitory Concentration Values for Bactrim-Susceptible Organisms MIC—mcg/ml

Bacteria	Trimethoprim alone	Sulfamethoxazole alone	TMP/SMX (1:20)	TMP	SMX
<i>Escherichia coli</i>	0.05-1.5	1.0-245	0.05-0.5	0.95-9.5	
<i>Proteus spp</i> indole positive	0.5-5.0	7.35-300	0.05-1.5	0.95-28.5	
<i>Proteus mirabilis</i>	0.5-1.5	7.35-30	0.05-0.15	0.95-2.85	
<i>Klebsiella-Enterobacter</i>	0.15-5.0	0.735-245	0.05-1.5	0.95-28.5	

Human Pharmacology: Bactrim is rapidly absorbed following oral administration. The blood levels of trimethoprim and sulfamethoxazole are similar to those achieved when each component is given alone. Peak blood levels for the individual components occur one to four hours after oral administration. The half-lives of sulfamethoxazole and trimethoprim, 10 and 16 hours respectively, are relatively the same regardless of whether these compounds are administered as individual components or as Bactrim. Detectable amounts of trimethoprim and sulfamethoxazole are present in the blood 24 hours after drug administration. Free sulfamethoxazole and trimethoprim blood levels are proportionately dose-dependent. On repeated administration, the steady-state ratio of trimethoprim to sulfamethoxazole in the blood is about 1:20.

Sulfamethoxazole exists in the blood as free, conjugated and protein-bound forms; trimethoprim is present as free, protein-bound and metabolized forms. The free forms are considered to be the therapeutically effective forms. Approximately 44 percent of trimethoprim and 70 percent of sulfamethoxazole are protein-bound in the blood. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim to an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole.

Excretion of Bactrim is chiefly by the kidney through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. When administered together as in Bactrim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.

Indications: Chronic urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) due to susceptible organisms (usually *E. coli*, *Klebsiella-Enterobacter*, *P. mirabilis*, and, less frequently, indole-positive proteus species).

Important note: Currently, the increasing frequency of resistant organisms is a limitation of the usefulness of all antibacterial agents, especially in the treatment of chronic and recurrent urinary tract infections.

Contraindications: Hypersensitivity to trimethoprim or sulfamethoxazole. Pregnancy and during the nursing period (see Reproduction Studies).

Warnings: Oedema associated with the administration of sulfamethoxazole has been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia and other blood dyscrasias. Experience with trimethoprim alone is much more limited, but it has been reported to interfere with hematopoiesis in occasional patients. In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported.

The presence of clinical signs such as sore throat, conjunctivitis, rash, fever, purpura or jaundice may be early indications of serious blood disorders. Complete blood counts should be done frequently in patients receiving Bactrim. If a significant reduction in the count of any formed blood element is noted, Bactrim should be discontinued.

At the present time, there is insufficient clinical information on the use of Bactrim in infants and children under 12 years of age to recommend its use.

Precautions: Bactrim should be given with caution to patients with impaired renal or hepatic function, to those with possible folate deficiency and to those with severe allergy or bronchial asthma. In glucose-6-phosphate dehydrogenase-deficient individuals, hemolytic may occur. This reaction is frequently dose-related. Adequate fluid intake must be maintained in order to prevent crystalluria and stone formation. Urinalysis with tests should be performed during therapy, particularly for those patients with impaired renal function.

Adverse Reactions: For completeness, all major reactions to sulfonamides and to trimethoprim are included below, even though they may not have been reported with Bactrim.

Blood dyscrasias: Agranulocytosis, aplastic anemia, megaloblastic anemia, thrombopenia, leukopenia, hemolytic anemia, purpura, hypoprothrombinemia and methamoglobinemia.

Allergic reactions: Erythema multiforme, Stevens-Johnson syndrome, generalized skin eruptions, epidermal necrolysis, urticaria, serum sickness, pruritus, exfoliative dermatitis, anaphylactic reactions, periorbital edema, conjunctival and scleral injection, photosensitivity, arthralgia and allergic myocarditis.

Gastrointestinal reactions: Gastrostitis, stomatitis, nausea, emesis, abdominal pains, hepatitis, diarrhea and pancreatitis.

C.N.S. reactions: Headache, peripheral neuritis, mental depression, convulsions, ataxia, hallucinations, tinnitus, vertigo, insomnia, apathy, fatigue, muscle weakness and nervousness.

Miscellaneous reactions: Drug fever, chills, and toxic nephritis with oliguria and anuria. Periorbital nodose and L.E. phenomenon have occurred.

The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Goiter production, diuretics and hypoglycemia have occurred rarely in patients receiving sulfonamides. Cross-sensitivity may exist with I-thiouracil agents. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term administration has produced thyroid malignancies in these species.

Dosage and Administration: Not recommended for use in children under 12 years of age. The usual adult dosage is two tablets every 12 hours for 10 to 14 days.

For patients with renal impairment:

Creatinine Clearance (ml/min)	Recommended Dosage Regimen
Above 30	Usual standard regimen
15-30	2 tablets every 24 hours
Below 15	Use not recommended

How Supplied: Tablets, containing 80 mg trimethoprim and 400 mg sulfamethoxazole—bottles of 100 and 500; Tel-E-Dose® packages of 1000; Prescription Paks of 40, available singly and in trays of 10. Imprint on tablets: ROCHE 50.

Reproduction Studies: In rats, doses of 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratological effects manifested mainly as cleft palates. The highest dose which did not cause cleft palates in rats was 512 mg/kg sulfamethoxazole or 192 mg/kg trimethoprim when administered separately. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. However, in one study, cleft palates were observed in one litter out of 9 when 355 mg/kg of sulfamethoxazole was used in combination with 88 mg/kg of trimethoprim.

In rabbits, trimethoprim administered by intubation from days 8 to 16 of pregnancy at dosages up to 500 mg/kg resulted in higher incidences of dead and resorbed fetuses, particularly at 500 mg/kg. However, there were no significant drug-related teratological effects.

BACTRIM™
Each tablet contains 80 mg trimethoprim and 400 mg sulfamethoxazole.
for chronic urinary tract infections

ROCHE Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, N.J. 07110

Wednesday, October 17, 1973

MEDICAL TRIBUNE

Virus May Trigger and Play Role in Multiple Sclerosis

Medical Tribune World Service

BARCELONA, SPAIN—A virus may not only trigger the chain of events leading to the development of multiple sclerosis but may also figure in the disease process itself, Dr. Hilary Koprowski, of the Wistar Institute, Philadelphia, told the 10th International Congress of Neurology here.

Dr. Koprowski based this view on two discoveries:

• The direct isolation of a virus from multiple sclerosis brain cells maintained in tissue culture.

• The demonstration of ultrastructural similarities if not identical nucleocapsids in brain cells obtained from early demyelinating lesions in a multiple sclerosis case.

Dr. Koprowski identified the virus or the 6/94 agent, a new member of the paramyxo virus type I group, it differs from the HA2 and Sendai (HVJ) prototype viruses with multiple sclerosis show greater reactivity to human or rabbit brain basic protein antigen.

It is much less cytocidal for cells in culture than either of the other two viruses, he said, and "can easily be used to establish a persistent type of infection of the cells."

Cells infected with the 6/94 agent, Dr. Koprowski reported, will hemadsorb guinea pig red blood cells when maintained at incubation temperature of 32° to 33° C. but not when grown at 37°.

"Subtle differences between the 6/94 and the Sendai viruses may also exist in the number of species of proteins and in patterns of various RNA components," he added.

May Cause Mild Infections

The Sendai and HA2 viruses have not been known to play a role in diseases of the central nervous system, he observed, but HA2 is a causative agent in relatively mild respiratory infections.

Dr. Koprowski stressed the point that kinds of paramyxo viruses are mainly determined by the host cells in which the viruses are propagated; thus the viruses that host cells have characteristics that are dependent upon the types of cells in which they reproduce. "Moreover, the fact that multiple sclerosis correlates with certain antigenic specificities may mean that it is possible that some individuals are genetically predisposed to react differently to an infection with a viral agent which in the rest of the population may cause only minor illnesses."

He cautioned that thus far there is, at best, only a hypothetical case for the role of 6/94 in multiple sclerosis, and noted

that there is indirect evidence of the roles of other viral agents.

Citing the higher concentrations of antibodies antibodies in the sera of multiple sclerosis patients, he said that "the presence of these antibodies, and antibodies directed against vaccinia viruses, in the central nervous system of multiple sclerosis patients may indicate such involvement."

Dr. Koprowski recommended "epidemiologic studies in high- and low-incidence areas, conducted along the pattern established for polio virus infections, as a means of elucidating the role of a virus in the etiology of multiple sclerosis."

In another paper presented at the conference, Dr. John Zabriskie, of Rockefeller University, New York, said that peripheral blood leukocytes from patients with multiple sclerosis show greater reactivity to human or rabbit brain basic protein antigen. Sulfur fluorescein dye, when used with indocyanine green, provides ophthalmologists with simultaneous photographs of both retina and choroid (above). The choroidal vascular system provides much of the nutrition for the retina and all of that for the central macular region.

Blood Flow in the Eye



BCG Administered Orally Effective in Stimulating Tumor Immune Response

Medical Tribune World Service

SALZBURG, AUSTRIA—Oral administration of lyophilized BCG in an attempt to stimulate immune response in the area of a tumor has been tried at the Connaught Laboratories in Toronto, and the results suggest that this method is sometimes effective.


Dr. R. E. Falk, of the University of Toronto, described the work to the 10th European Assembly on Cytology and Cancer Prevention here.

Sixty patients with disseminated malignant melanoma or carcinoma of the gastrointestinal tract were given oral BCG over a 16-month period. They received 120 mg, at least weekly, the dose being decreased if there was objective regression. Of 14 patients with disseminated melanoma, objective regression was noted in eight, Dr. Falk reported. The therapy was ineffective in patients with advanced hepatic metastases. All patients who responded with tumor regression showed enhanced reactivity to both tumor membrane antigens and BCG in vitro tests.

INJECTABLE




INGESTIBLE




BREATHABLE



DROPPABLE



SPRAYABLE



DECADRON®
(DEXAMETHASONE|MSD)

MSD
MERCK
DORME

DIVISION OF MERCK & CO., INC., WEST POINT, PA. 19486

R.S.V.P.



Ritalin® (methylphenidate) helps the patient respond in mild depression*

*This drug has been evaluated as possibly effective for this indication. See brief prescribing information.

Ritalin® hydrochloride
(methylphenidate hydrochloride)
TABLETS

INDICATION
Based on a review of this drug by the National Academy of Sciences-National Research Council and for other information, FDA has classified the indication as follows: "Possibly" effective: Mild depression. Final classification of this less-than-effective indication requires further investigation.

CONTRAINdications
Marked oxylate, lassitude, and agitation, since Ritalin may aggravate these symptoms. Also contraindicated in patients known to be hypersensitive to the drug and in patients with glaucoma.

WARNINGS
Ritalin should not be used in children under 6 years, since safety and efficacy in this age group have not been established. Sufficient data on safety and efficacy of long-term use of Ritalin in children with normal brain dysfunction are not yet available, although a causal relationship has not been established, suppression of growth (i.e., weight gain and height) has been reported with long-term use of Ritalin in children. Therefore, children receiving long-term therapy should be carefully monitored. Ritalin should not be used for severe depression of either exogenous or endogenous origin or for the prevention of normal fatigue episodes. Ritalin may lower the convulsive threshold in patients with or without prior seizures, with or without prior EEG abnormalities, even in absence of seizures. Safe concomitant use of anticonvulsants and Ritalin has not been established. Use cautiously in patients with hypertension. Blood pressure should be monitored at appropriate intervals in all patients taking Ritalin, especially those with hypertension.

DRUG INTERACTIONS
Ritalin may decrease the hypotensive effect of guanethidine and other centrally acting pressor agents and MAO inhibitors. Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic antidepressants (imipramine, desipramine). Downward dosage adjustments of these drugs may be required when given concomitantly with Ritalin.

USAGE IN PREGNANCY
Adequate animal reproduction studies to establish safe use of Ritalin during pregnancy have not been conducted. Therefore, until more information is available, Ritalin should not be prescribed for women of childbearing age unless in the opinion of the physician, the potential benefits outweigh the possible risks.

DRUG DEPENDENCE
Ritalin should be given cautiously to emotionally unstable patients, such as those with a history of drug dependence or alcoholism, because such patients may increase dosage on their own initiative. Chronically abusive use can lead to marked tolerance and psychic dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with psychotropics. Careful supervision is required during drug withdrawal, since severe depression, as well as the effects of chronic overactivity can be manifested. Long-term follow-up may be required because of the patient's basic personality disturbances.

PRECAUTIONS
Patients with an element of agitation may need non-pharmacological therapy if necessary. Periodic CBC, differential, and platelet counts are advised during prolonged therapy.

ADVERSE REACTIONS
Nervousness and insomnia are the most common adverse reactions and are usually controlled by reducing dosage and omitting the drug in the afternoon or evening. Other reactions include: hypersensitivity (including skin rash, urticaria, fever, anaphylaxis, exfoliative dermatitis, rashes, multiformes with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); anorexia; nausea; dizziness; palpitation; headache; dyskinetic; drowsiness; blood pressure changes; diarrhea; constipation; tachycardia; dizziness; abdominal pain; weight loss during prolonged therapy. Toxic psychosis has been reported. Although a definite causal relationship has not been established, the following has been reported in patients taking this drug: leukopenia and/or anemia; few instances of scalp hair loss; in children, loss of appetite; abdominal pain; weight loss during prolonged therapy; insomnia; and tachycardia may occur more frequently; however, any of the other adverse reactions listed above may also occur.

DOSEAGE AND ADMINISTRATION
Adults: Administer orally in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Dosage will depend upon indication and individual response.

Average dosage to 20 to 60 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. The few patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.

HOW SUPPLIED
Tablets, 20 mg (peach, scored); bottles of 100 and 1000.
Tablets, 10 mg (pale green, scored); bottles of 100, 200, 1000 and Accu-peel blister units of 100.
Tablets, 5 mg (pale yellow); bottles of 100, 200 and 1000.
Consult complete product literature before prescribing.

CIBA Pharmaceutical Company
Division of CIBA-GEIGY Corporation
Summit, New Jersey 07901

C I B A

Wednesday, October 17, 1973

MEDICAL TRIBUNE

The Only Independent Weekly Medical Newspaper in the U.S.

Medical Tribune

Medical News
Published by Medical Tribune, Inc.

Advisory Board

JOHN ADRIANI, M.D. • JAMES H. MANSERIAN, M.D. • ROBERT A. CHASO, M.D.
RENE J. DUBOS, Ph.D. • ALTON OCUMMER, M.D. • BERNARD LOWN, M.D.
LEO G. RHEIN, M.D. • ALBERT H. SAHN, M.D.

ARTHUR M. SACKLER, M.D.
International Publisher

ALEXANDER STOIA
Publisher

JOHN O'KEARNY
Executive News Editor

RICHARD S. CURNER, M.D.
Associate Editor

NATHAN HORWITZ
Special News Editor

WILLIAM PRIFTIS
Layout Editor

NIKKI FROST
Picture Editor

880 Third Avenue, New York, N.Y. 10022 • Telephone: 421-4000
Circulation audited by Business Publications Audit of Circulation, Inc.



"A lot of good those get-well cards did him!"

© 1973 Medical Tribune

I. Scapegoats, Washington—and Doctors

ONE SAOLY NOTES how essential the scapegoat is to the Washington scene. Attention must be drawn to a clear pattern that has existed through several administrations—a pattern of making the physician the scapegoat for the real, pressing, and complex problems of public health. We know that virtually all consider alcohol and tobacco as two of the leading preventable causes of disease. We know of no evidence that a reduction in physicians' fees or lower cost of medications can for any significant period of time arrest the escalating cost of catastrophic disease or of hospital costs. We do know that adequate numbers of physicians and new medications have in the past reduced what would today have been an intolerable burden—the costs of care through preventative and curative medicine in acute and infectious disease, tuberculosis, psychiatric disorders, etc.

The selective efforts exercised by governmental agencies focusing headlines on minor issues are worse than nothing because they mislead the public as well as the profession and defer the day when real issues will be realistically examined, defined, and solved.

Terminology and Cancer

ONE OF THE PRINCIPLES of ever-honoring science is the introduction of terms and phrases that are clear to the initiate but pose problems to the rest of us; the latest editions of dictionaries are turned in vain, and no ready reference is available.

One of the hot investigative areas currently is the effort to incriminate viruses as causes of human cancer, and especially one reads of RNA viruses, type B particles. Presumably there are at least also type A and other particles. But what are they? It is comforting to learn from an editorial in an issue of the *Journal of the National Cancer Institute* that even experts have been confounded, and as recently as last year the statement was made that "confusion continues to surround the terminology used to categorize members of the RNA tumor virus group."

Of course, the intriguing element about all this is that for a number of years B-type particles have been found in high incidence in human milk from women known to be at high familial risk of mammary cancer. Work in Spiegelman's laboratory and elsewhere has added evidence that these particles may indeed be the cause of human cancer of the breast, but the crucial transmission experiment that demonstrated the neoplastic effect of B particles in the mouse is, of course, forbidden in man. Lower primates can be tested and persuasive proof may be forthcoming.

Vitamin E and Angina

CLINICAL QUOTE: "There would appear to be two possible explanations for the failure of . . . double-blind trials to confirm the dramatic effects that have been reported by some authors. Either that vitamin E is of no value (and the favorable reports are due entirely to a combination of spontaneous remission and

On Vitamin C

In response to Dr. J. W. Meigs ("Letters to Tribune," September 26):

I am one of those unfortunate people who had to suffer severe colds through years, since childhood.

For the past three years, I have not had any colds, since I take routinely at least 2 Gm. of vitamin C, and at the first signs of a suspected cold I increase the dosage to at least 3 Gm. per day. The cold does not develop. I take vitamin C always after or during meals, not on an empty stomach.

NINA TOLL, M.D.
Middletown, Conn.

A Kick About Feet

In your Aug 22 issue you carried an entire section related to foot disorders in runners. The lead article regarded a talk given by Dr. George Sheehan, a cardiologist, regarding foot problems, before the California College of Podiatric Medicine. He was quoted as stating "90 per cent of doctors know nothing about the foot, and orthopedic surgeons have never helped."

Naturally, as an orthopedic surgeon, I differ with his opinion. I do not feel the need to defend my specialty nor go into a point-by-point discussion of the various issues raised in these articles. However, I am curious to know whether Dr. Sheehan's orthopedic colleagues think as highly of him as a cardiologist as he does of them.

HOWARD STURTZ, M.D.
Walnut Creek, Calif.

All in Favor Say 'Da'

In your recent article about the latest socialist outburst of Senator Kennedy, proposing peer review of doctors by pharmacists, he wonders, at the end, "whether we need five or more companies manufacturing identical products."

If we look at Russia's example, we could do without four of them. Only one, owned and operated by the Government, is needed. Also, following Russia's example, we could do without senators and millionaires.

SERORO M. ACOSTA, M.D.
Elmhurst, Ill.

Acusing Finger

The psychotherapeutic effect of Oral Valium® (diazepam)

in anxiety and somatic symptoms of excessive psychic tension

When a complete examination rules out organic disease, you may find that functional complaints involving the heart, stomach or colon—frequently seen in anxious patients overreacting to stress—are a result of excessive psychic tension. And if counseling alone does not suffice, you might consider Valium (diazepam) to help relieve these tension-induced symptoms. In general, it goes to work promptly.

usually producing significant improvement within the first few days of therapy, although some patients may take longer to show a clear-cut response.

Available in three convenient tablet strengths—2 mg, 5 mg, 10 mg—Valium provides dosage flexibility for maximum patient benefit with a typical *t.i.d.* or *q.i.d.* regimen.



16



in anxiety with or without associated depressive symptoms in psychoneurotics

Valium (diazepam) can provide prompt relief when excessive anxiety and undue tension are a prominent part of the clinical picture. By relieving these symptoms, it can enhance response to therapy and add to the effectiveness of your total management of the psychoneurotic patient. Caution patients against driving or engaging in hazardous activities during therapy.

The recommended dosage is 2 to 10 mg, *b.i.d.* to *q.i.d.*, depending upon the severity of symptoms.



adjunctively in organic disorders complicated by undue psychic tension

Overly tense patients—particularly those with G.I. or cardiac disease—must be kept calm when undue tension and excessive anxiety aggravate their condition and interfere with therapy. Oral Valium can provide the desired response, generally without significantly adversely affecting respiratory, pulse or heart rates. It is used with most classes of primary medications such as cardiac glycosides, diuretics, vasodilators, anticholinergics and antacids, and is usually well tolerated; the most frequent side effects are drowsiness, fatigue and ataxia.

When nighttime anxiety precludes sleep, an *h.s.* dose added to the *t.i.d.* regimen can relieve the anxiety.

Please see the last page of this advertisement for complete prescribing information.

17

The psychotherapeutic effect of Injectable Valium® (diazepam)

prior to surgery

Injectable Valium (diazepam) can promptly calm the surgical patient by lessening the excessive anxiety and unease that may be associated with strange surroundings and disturbing procedures. And it can provide the added advantage of markedly diminishing recall of preoperative procedures.

The recommended dosage is 10 mg, I.M., administered one to two hours preoperatively. Injectable Valium should not be mixed or diluted with other drugs, solutions or fluids.



adjunctively prior to gastroscopy and esophagoscopy

Injectable Valium (diazepam) can be a valuable adjunct in allaying excessive anxiety when it accompanies such procedures. It calms the anxiety yet allows the patient to cooperate by responding to commands and following instructions. It is not recommended for bronchoscopy and laryngoscopy. Because of the possibility of laryngospasm, necessary countermeasures and resuscitative facilities should be immediately available.

Half an hour before gastroscopy or esophagoscopy, a 5 to 10-mg dose is administered I.M. or I.V.



prior to cardioversion

Through relief of undue anxiety and excessive tension, Injectable Valium (diazepam) can effectively calm the patient. Memory of the cardioversion procedure can be markedly diminished. Injectable Valium seldom significantly alters vital signs. Nevertheless, there have been infrequent reports of hypotension and rare reports of apnea and cardiac arrest. Resuscitative facilities should be immediately available.

Five to ten minutes before elective cardioversion, the recommended dosage is 5 to 15 mg, injected slowly I.V. (5 mg/min).



The anticonvulsant effect of Valium® (diazepam)

adjunctively in certain convulsive disorders

Injectable Valium (diazepam) has usually been an effective adjunct in interrupting status epilepticus promptly, sometimes in a matter of seconds. It has helped provide control with the first injection, frequently with prolonged relief. Oral Valium may be used adjunctively in certain convulsive disorders such as petit mal or myoclonic seizures, although it has not proved useful as sole therapy.

In status epilepticus and severe recurrent convulsive seizures, 5 to 10 mg, injected slowly I.V.—5 mg (1 ml)/minute. Use I.M. route if slow I.V. injection is not feasible. Do not mix or dilute with other drugs, solutions or fluids. Repeat in 2 to 4 hours, if necessary. The dosage for Oral Valium used adjunctively is 2 to 10 mg, 3 or 4 times a day.



Please see the last page of this advertisement for complete prescribing information.

The skeletal muscle relaxant effect of Valium® (diazepam)

adjunctively in skeletal muscle spasm caused by local pathology

As part of the therapeutic regimen, Valium (diazepam) orally or parenterally, as appropriate, can help relieve skeletal muscle spasm due to reflex spasm caused by local pathology, such as inflammation of muscles or joints, or associated with muscle strains. It can help break the spasm/pain/spasm cycle and thus may increase mobility. Usual oral dosage is 2 to 10 mg on a *t.i.d.* or *q.i.d.* schedule.

Usual injectable dosage is 5 to 10 mg *I.M.* or *I.V.* initially, then 5 to 10 mg in 3 to 4 hours, if necessary. In elderly or debilitated patients, it is recommended that oral dosage be limited to the smallest effective amount to preclude the development of ataxia or oversedation (2 to 2½ mg once or twice daily, initially, to be increased gradually as needed and tolerated).



adjunctively in spasticity associated with paraplegia

In upper motor neuron disorders causing paraplegia, the adjunctive use of Valium (diazepam) can help reduce skeletal muscle spasticity. Valium offers a wide margin of safety due to its relatively low toxicity. Isolated reports of neutropenia and jaundice make periodic blood counts and liver function tests advisable during long-term therapy.

Three convenient tablet strengths—2 mg, 5 mg, 10 mg—allow wide adjustments in dosage for the greatest efficacy in clinical response. And injectable Valium may be used, where appropriate, in the usual dosage for muscle spasm.

adjunctively in spasticity due to cerebral palsy or athetosis

The skeletal muscle relaxant effect of Valium (diazepam) makes it a valuable adjunct in reducing spasticity. It may thus aid by reducing involuntary movements and improving voluntary performance and speech. This may result in more patient cooperation and confidence during therapy. Valium is generally well tolerated; drowsiness has been the biggest problem among responsive athetoid children. The possible side effect of ataxia may limit its usefulness in ataxic children.

Dosage should be individualized for maximum patient benefit. However, the usual recommendation is 2 to 10 mg *t.i.d.* or *q.i.d.* Where parenteral therapy is indicated, use 5 to 10 mg *I.M.* or *I.V.* initially, then 5 to 10 mg in 3 to 4 hours, if necessary. Oral Valium is contraindicated in children under 6 months. Injectables Valium is contraindicated in infants and its safety and efficacy in children under 12 have not been established.



For three different effects:
psychotherapeutic
anticonvulsant
skeletal muscle relaxant

Valium®
(diazepam)

parenterally in stiff-man syndrome or in tetanus

Injectable Valium (diazepam), used adjunctively, can reduce characteristic skeletal muscle spasm and resulting rigidity. Response is usually prompt and improvement sustained in the control of muscular rigidity and convulsive spasms. In general, Valium can thus help improve range of mobility. Periodic blood counts and liver function tests are advisable during long-term therapy. Only the parenteral form of Valium (diazepam) is indicated for tetanus. Usual *I.M.* or *I.V.* dosage recommendation is 5 to 10 mg; for tetanus, larger doses may be required. A repeat dose, if necessary, may be administered in 3 to 4 hours.

Please see the following page for complete prescribing information.

Valium® (diazepam)

2-mg, 5-mg, 10-mg tablets

ready-to-use 2-ml Tel-E-Ject® (disposable syringes)
10-ml vials 5 mg/ml
2-ml ampuls

Complete Prescribing Information:

Desiredon (ORAL AND INJECTABLE): Valium (diazepam) is a benzodiazepine derivative developed through original Roche research. Chemically, diazepam is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. It is a colorless, crystalline compound, insoluble in water and has a molecular weight of 284.74.

Pharmacology (ORAL AND INJECTABLE): In animals Valium (diazepam) appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Valium (diazepam), unlike chlorpromazine and reserpine, has no demonstrable peripheral anticholinergic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with Valium (diazepam) do have transient ataxia at higher doses. Valium (diazepam) was found to have transient cardiovascular depressor effects in dogs. Long term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.

Oral LD₅₀: Valium is 720 mg/kg in mice and 1240 mg/kg in rats. Intraperitoneal administration of 400 mg/kg to a monkey resulted in death on the sixth day.

Reproduction Studies: A series of rat reproduction studies was performed with diazepam in oral doses of 1, 10, 80 and 100 mg/kg. At 100 mg/kg there was a decrease in the number of pregnancies and surviving offspring in these rats. Normal survival of rats at doses lower than 100 mg/kg was within normal limits. Several neonates in these rat reproduction studies showed skeletal or other defects. Further studies in rats at doses up to and including 80 mg/kg/day did not reveal teratological effect on the offspring.

In humans, measurable blood levels of Valium (diazepam) were obtained in maternal and cord blood, indicating placental transfer of the drug.

Indications:

ORAL AND INJECTABLE: Valium (diazepam) is useful in the symptomatic relief of tension and anxiety states resulting from stressful circumstances or whenever somatic complaints are concomitants of emotional factors. It is useful in psychoneurotic states manifested by tension, anxiety, apprehension, fatigue, depressive symptoms or agitation.

In acute alcohol withdrawal, Valium (diazepam) may be useful in the symptomatic relief of acute agitation, tremor, impending or tonic delirious terrors and hallucinations. Valium (diazepam) is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasm caused by upper motor neuron disorders (such as cerebral palsy and paraparesis); ataxia; stiff-man syndrome. Oral: Oral Valium (diazepam) may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

INJECTABLE: If apprehension, anxiety and acute stress reactions are present prior to gastroscopy and esophagoscopy, injectable Valium (diazepam) may be a valuable adjunct. (See Precautions.)

Injectable Valium (diazepam) is a useful adjunct in *in situ* epilepticus and severe recurrent convulsive seizures, and in tetanus.

Valium (diazepam) is a useful premedication (i.m. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, it is also useful prior to cardiopulmonary. In either instance, the patient's recall of the procedure is markedly diminished.

Contraindications:

ORAL: Valium (diazepam) is contraindicated in patients with a known hypersensitivity to this drug and, because of lack of sufficient clinical experience, in children under 6 months of age. It may be used in patients with open angle glaucoma who are receiving appropriate therapy, but is contraindicated in acute narrow angle glaucoma.

INJECTABLE: Injectable Valium (diazepam) is contraindicated in infants and in patients with a known hypersensitivity to this drug. It may be used in patients with open angle glaucoma who are receiving appropriate therapy, but is contraindicated in acute narrow angle glaucoma.

Warnings: As is true of most CNS-acting drugs, patients receiving Valium (diazepam) should be cautioned against engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle.

Since Valium (diazepam) has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during Valium (diazepam) therapy.

ORAL: Valium (diazepam) is not of value in the treatment of psychotic patients and should not be employed in lieu of appropriate treatment.

As with other agents which have an anticonvulsant activity, when Valium (diazepam) is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dose of standard anticonvulsant medication. Abrupt withdrawal of Valium (diazepam) in such cases may also be associated with a temporary increase in the frequency and/or severity of seizures.

INJECTABLE: When used intravenously the solution should be injected slowly, directly into the vein, taking at least one minute for each 5 mg (1 ml) given. Do not mix or dilute injectable Valium (diazepam) with other solutions or drugs. Do not add to i.v. fluids. Rare reports of apnea or cardiac arrest have been noted, usually following i.v. administration, especially in elderly or very ill patients and those with limited pulmonary reserve. Duration is generally brief. Resuscitative facilities should be available.

Injectable Valium (diazepam) is not recommended as the sole treatment for psychotic or severely depressed patients. Injectable Valium (diazepam) should not be administered to patients in shock, coma, or in acute alcohol intoxication with depression of vital signs.

Physical and Psychological Dependence: Withdrawal symptoms (similar in character to those noted with barbiturates and alcohol) have occurred following abrupt discontinuation of diazepam (convulsions, tremor, ataxia, and muscle cramps, vomiting and sweating). These were usually limited to those patients who had received excessive doses over an extended period of time. Particularly individuals prone to drug addiction (such as drug addicts or alcoholics) should be under careful surveillance when receiving diazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence.

Use in Pregnancy: Use of any drug in pregnancy, lactation or in women of childbearing age requires that the potential benefit of the drug be weighed against its possible hazard to mother and child. (See Reproduction Studies.)

Management of Overdose: Manifestations of Valium (diazepam) overdose include somnolence, confusion, coma and diminished reflexes. Respiration should be monitored and pressure should be monitored, as in all cases of drug overdose, although, in general, these effects have been minimal following overdose. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be combated by the use of Loproped® (dearterenol) or Aramine (metaraminol). Ritalin (methylphenidate) or caffeine and sodium benzoate may be given to combat CNS-depressive effects. Dialysis is of limited value. As with the management of intentional overdoses with any drug, it should be borne in mind that multiple agents may have been ingested.

Precautions: **ORAL AND INJECTABLE:** If Valium (diazepam) is to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed—particularly with known compounds which may potentiate the action of Valium (diazepam), such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants. The usual precautions are indicated for severely depressed patients or those in whom there is any evidence of latent depression; particularly the recognition that suicidal tendencies may be present and protective measures may be necessary. The usual precautions in treating patients with impaired renal or hepatic function should be observed.

Oral: In elderly and debilitated patients, it is recommended that the dosage be limited to the smallest effective amount to prevent the development of ataxia or oversedation (2 mg to 2 1/2 mg once or twice daily, initially, to be increased gradually as needed and tolerated). In injectable Valium (diazepam) is not recommended for bronchoscopy and laryngoscopy, because increased cough reflex and laryngospasm have been reported. Furthermore, possible reflex and necessary countermeasures should be efficacy is available. Injectable diazepam is not recommended for obstetric use or in diagnostic procedures other than bronchoscopy and esophagoscopy.

Injectable Valium (diazepam) has produced hypotension or muscular weakness in some patients, particularly when used with narcotics, barbiturates or alcohol. Since Valium (diazepam) may have an additive effect with narcotics, appropriate reduction in narcotic dosage is possible. Lower doses (usually 2 mg to 5 mg) should be used for elderly and debilitated patients.

The safety and efficacy of injectable Valium (diazepam) in children under age 12 have not been established.

Adverse Reactions:


ORAL AND INJECTABLE: Because of isolated reports of neuroleptics and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy. Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after Valium (diazepam) therapy and are of known significance.

ORAL: Side effects most commonly reported were drowsiness, fatigue and ataxia. Infrequently encountered were confusion, diplopia, dysarthria, headache, nausea, change in salivation, skin rash, blurred speech, tremor, urinary retention, vertigo and blurred vision. Paroxysmal reactions such as acute hypereccited states, anxiety, sleep disturbances and stimulation have been reported; should these occur, use of the drug should be discontinued.

INJECTABLE: Side effects most commonly reported were drowsiness, fatigue and ataxia. Infrequently encountered were confusion, constipation, depression, diplopia, dysarthria, headache, hiccup, hypoesthesia, hypotension, incontinence, changes in salivation, nausea, phlebitis at injection site, tremor, urinary retention, vertigo and blurred vision. Paroxysmal reactions such as acute hypereccited states, anxiety, sleep disturbances and stimulation have been reported; should these occur, use of the drug should be discontinued.

Dosage and Administration:

ORAL: Dose should be individualized for maximum beneficial effect. While the usual daily doses given below will meet the needs of most patients, there will be some who may require higher doses. In such cases dosage should be increased cautiously to avoid adverse effects.



Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, N.J. 07110

Adults:
Symptomatic Relief of Tension and Anxiety States and Psychoneurotic States
Alcohol Withdrawal

USUAL DAILY DOSE
Depending upon severity of symptoms—2 mg to 10 mg, 2 to 4 times daily
10 mg, 3 or 4 times during the first 24 hours, reducing to 5 mg, 3 or 4 times daily as needed
2 mg to 10 mg, 3 or 4 times daily
2 mg to 10 mg, 2 to 4 times daily
2 mg to 2 1/2 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated

Children:
Because of varied responses to CNS-acting drugs, initiate therapy with lowest dose and increase as required. Not for use in children under 6 months.

ADULTS:
Dose should be individualized for maximum beneficial effect. In acute conditions the injection may be repeated within one hour although an interval of 3 to 4 hours is usually satisfactory. Generally not more than 50 mg should be given within an 8-hour period.

INJECTION: Injectables Valium (diazepam) should be injected directly into the muscle.

INSTRUCTIONS: The injection should be injected slowly, directly into the vein, taking at least one minute for each 5 mg (1 ml) given. Do not mix or dilute. Injectables Valium (diazepam) with other solutions or drugs. Do not add to i.v. fluids.

USUAL DOSAGE*

2 mg to 5 mg, I.M. or I.V.
Repeat in 3 to 4 hours, if necessary.

5 mg to 10 mg, I.M. or I.V.
Repeat in 3 to 4 hours, if necessary.

10 mg, I.M. or I.V. initially, then 5 mg to 10 mg in 3 to 4 hours, if necessary.

5 mg to 10 mg, I.M. or I.V., approximately 30 minutes prior to the procedure.

5 mg to 10 mg, I.M. or I.V. initially, then 5 mg to 10 mg in 3 to 4 hours, if necessary. For tetanus, larger doses may be required.

5 mg to 10 mg, I.M. or I.V. initially. Repeat in 2 to 4 hours, if necessary.

10 mg, I.M. (preferred route), 1 to 2 hours before surgery.

5 mg to 15 mg, I.V. within 5 to 10 minutes prior to the procedure.

*Lower doses (usually 2 mg to 5 mg) and slow increase in dosage should be used for elderly or debilitated patients and when other sedative drugs are administered. (See "Precautions and Adverse Reactions".)

Once the acute symptomatology has been properly controlled with injectable Valium (diazepam), the patient may be placed on oral therapy with Valium (diazepam) if further treatment is required.

How Supplied:

ORAL: Valium (diazepam) scored tablets—2 mg, white; 5 mg, yellow; and 10 mg, blue—bottles of 100 and 500. All strengths also available in Tel-E-Dose® packages of 1000.

INJECTABLE: Ampuls, 2 ml, boxes of 10; Vials, 10 ml, boxes of 1; Tel-E-Ject® (disposable syringes), 2 ml, boxes of 10. Each ml contains 5 mg diazepam compounded with 40% propylene glycol, 10% ethyl alcohol, 5% sodium benzoate and benzoic acid as buffers, and 1.5% benzyl alcohol as preservative.

Antigen Barred as Colorectal Cancer Screen

Medical Tribune Report

BAL HARBOUR, FLA.—Carcinoembryonic antigen (CEA), though useful for diagnosis of colorectal cancer, lacks specificity for use in screening, a study by the National Cancer Institute of Canada and the American Cancer Society concludes.

Specimens were studied at four university centers in the United States, with the Montreal General Hospital laboratory serving as reference center. Of the 503 patients admitted to the study, 146 had cancer of the colon or rectum; 62 per cent of preoperative specimens from these patients were positive for CEA, while 53 per cent of specimens from patients with other types of cancer and 29 per cent of patients with other diagnoses, Anthony B. Miller, M.B., of the Canadian institute, reported at the American Cancer Society's second National Conference on Cancer of the Colon and Rectum here.

Dr. Norman Zamcheck, Harvard Medi-

cal School, confirmed both the positive correlation between poor prognosis and high preoperative CEA levels and the relative nonspecificity of CEA. Assays are positive in 45-60 per cent of early, resectable colorectal cancer patients and in 90 per cent of late or metastatic cases. When section of the primary colonic malignancy is complete, previously elevated CEA levels usually drop, he noted.

Though CEA is not specific for cancers

of the digestive tract—assays are also positive for noncolorectal cancers and for such nonneoplastic diseases as cirrhosis of the liver, alcoholic pancreatitis, and ulcerative colitis—the levels in benign diseases are lower than in malignancies.

Dr. Zamcheck stressed that quantitative, not qualitative, differences in the amount of circulating CEA are useful clinically, that the assays cannot substitute for complete clinical and laboratory study, and that they are not useful for making a specific diagnosis of colon cancer in screening patients.

of the digestive tract—assays are also positive for noncolorectal cancers and for such nonneoplastic diseases as cirrhosis of the liver, alcoholic pancreatitis, and ulcerative colitis—the levels in benign diseases are lower than in malignancies.

Dr. Zamcheck stressed that quantitative, not qualitative, differences in the amount of circulating CEA are useful clinically, that the assays cannot substitute for complete clinical and laboratory study, and that they are not useful for making a specific diagnosis of colon cancer in screening patients.

Disease Like Diabetes Affects Some Animals

Medical Tribune World Service

BRUSSELS—A wide range of animal species are affected by a syndrome closely resembling diabetes mellitus in man.

The list so far includes not only domestic animals but also a hippopotamus in New Zealand obese mice at some point during the evolution of their syndrome, and for the spiny mice, *Acomys cahirinus*, in which insulin secretion is decreased throughout life.

In some instances insulin secretion is decreased relatively early in the life of the predisposed animals, Dr. Renold said.

This is true for certain sublines of the Chinese hamster, for New Zealand obese mice at some point during the evolution of their syndrome, and for the spiny mice, *Acomys cahirinus*, in which insulin secretion is decreased throughout life.

In the medical management of obesity...

early weight loss can be critical to patient motivation.



Merrell

Tenuate®
(diethylpropion hydrochloride N.E.)

Merrell

the long-range analgesic

in chronic pain: continued relief without risk of tolerance

Though Talwin® Tablets can be compared to codeine in analgesic efficacy, Talwin is not subject to narcotic controls. For patients who require potent analgesia for prolonged periods, Talwin can provide consistent, long-range relief, with fewer of the consequences you've come to expect with narcotic analgesics.

• Comparable to codeine in analgesic efficacy: one 50 mg. Talwin Tablet appears equivalent in analgesic effect to 60 mg. (1 gr.) of codeine. Onset of significant analgesia usually occurs within 15 to 30 minutes. Analgesia is usually maintained for 3 hours or longer.

• Tolerance not a problem: tolerance to the analgesic effect of Talwin Tablets has not been reported, and no significant changes in clinical laboratory parameters attributable to the drug have been reported.

• Dependence rarely a problem: during three years of wide clinical use, only a few cases of dependence have been reported. *In prescribing Talwin for chronic use, the physician should take precautions to avoid increases in dose by the patient and to prevent the use of the drug in anticipation of pain rather than for the relief of pain.*

• Not subject to narcotic controls: convenient to prescribe—day or night—even by phone.

• Generally well tolerated by most patients: infrequently cause decrease in blood pressure or tachycardia; rarely cause respiratory depression or urinary retention; seldom cause diarrhea or constipation. If dizziness, lightheadedness, nausea or vomiting are encountered, these effects may decrease or disappear after the first few doses. (See next page of this advertisement for a complete discussion of Adverse Reactions and a Brief Summary of other Prescribing Information.)

50mg. Tablets

Talwin®
brand of
pentazocine
(as hydrochloride)
in moderate to severe pain

Wednesday, October 17, 1973

MEICAL TRIBUNE

in chronic pain: continued relief without risk of tolerance

Talwin® Tablets brand of pentazocine (as hydrochloride)

Analgesic for Oral Use—Brief Summary

Indications: For the relief of moderate to severe pain. Contraindication: Talwin should not be administered to patients who are hypersensitive to it.

Warnings: Drug Dependence. There have been instances of psychological and physical dependence on parenteral Talwin in patients with a history of drug abuse and, rarely, in patients without such a history. Abrupt discontinuance following the extended use of parenteral Talwin has resulted in withdrawal symptoms. There have been a few reports of dependence and of withdrawal symptoms with orally administered Talwin. Patients with a history of drug dependence should be under close supervision while receiving Talwin orally.

In prescribing Talwin for chronic use, the physician should take precautions to avoid increases in dose by the patient and to prevent the use of the drug in anticipation of pain rather than for the relief of pain.

Head Injury and Increased Intracranial Pressure. The respiratory depressant effects of Talwin and its potential for elevating cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, Talwin can produce effects which may obscure the clinical course of patients with head injuries. In such patients, Talwin must be used with extreme caution and only if its use is deemed essential.

Usage in Pregnancy. Safe use of Talwin during pregnancy (other than labor) has not

been established. Animal reproduction studies have not demonstrated teratogenic or embryotoxic effects. However, Talwin should be administered to pregnant patients (other than labor) only when, in the judgment of the physician, the potential benefits outweigh the possible hazards. Patients receiving Talwin during labor have experienced no adverse effects other than those that occur with commonly used analgesics. Talwin should be used with caution in women delivering premature infants.

Acute CNS Manifestations. Patients receiving therapeutic doses of Talwin have experienced, in rare instances, hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be very closely observed and vital signs checked. If the drug is discontinued it should be done with caution since the acute CNS manifestations may recur.

Usage in Children. Because clinical experience in children under 12 years of age is limited, administration of Talwin in this age group is not recommended.

Ambulatory Patients. Since sedation, dizziness, and occasional euphoria have been noted, ambulatory patients should be warned not to operate machinery, drive cars, or necessarily expose themselves to hazards.

Precautions: Certain Respiratory Conditions. Although respiratory depression has rarely been reported after oral administration of Talwin, the drug should be administered with caution to patients with respiratory depression from any cause, severe bronchial asthma and other obstructive respiratory conditions, or cyanosis.

Impaired Renal or Hepatic Function. Decreased metabolism of the drug by the liver in extensive liver disease may predispose to accumulation of side effects. Although laboratory tests have not indicated that Talwin causes increases renal or hepatic impairment, the drug should be administered with caution to patients with such impairment.

Myocardial Infarction. As with all drugs, Talwin should be used with caution in patients with myocardial infarction who have nausea or vomiting.

Biliary Surgery. Until further experience is gained with the effects of Talwin on the sphincter of Oddi, the drug should be used with caution in patients about to undergo surgery of the biliary tract.

Patients Receiving Narcotics. Talwin is a mild narcotic antagonist. Some patients previously given narcotics, including methadone for the initial treatment of narcotic dependence, have experienced mild withdrawal symptoms after receiving Talwin.

CNS Effect. Caution should be used when Talwin is administered to patients prone to seizures; seizures have occurred in a few such patients in association with the use of Talwin although no cause and effect relationship has been established.

Adverse Reactions: Reactions reported after oral administration of Talwin include gastritis/nausea; nausea, vomiting; infrequent constipation; and rarely abdominal distress, anorexia, diarrhea. CNS effects: dizziness, lightheadedness, sedation, euphoria, headache; infrequently weakness, disturbed dreams, insomnia, syncope, visual blurring and focusing difficulty, hallucinations (see Acute CNS Manifestations under WARNINGS); and rarely tremor, irritability, excitement, insomnia. Autonomic: sweating; infrequent flushing and rarely chills. Allergic: infrequently rash; and rarely urticaria, edema of the face. Cardiovascular: infrequently decrease in blood pressure, tachycardia. Other: rarely respiratory depression, urinary retention.

Dosage and Administration: Adults. The usual initial adult dose is 1 tablet (50 mg.) every three or four hours. This may be increased to 2 tablets (100 mg.) when needed. Total daily dosage should not exceed 600 mg.

When antiinflammatory or antipyretic effects are desired in addition to analgesia, aspirin can be administered concomitantly with Talwin.

Children Under 12 Years of Age. Since clinical experience in children under 12 years of age is limited, administration of Talwin in this age group is not recommended.

Duration of Therapy. Patients with chronic pain who have received Talwin orally for prolonged periods have not experienced withdrawal symptoms even when administration was abruptly discontinued (see WARNINGS). No tolerance to the analgesic effect has been observed. Laboratory tests of blood and urine and of liver and kidney function have revealed no significant abnormalities after prolonged administration of Talwin.

Overdosage Manifestations. Clinical experience with Talwin overdosage has been insufficient to define the signs of this condition.

Treatment. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. Although nalorphine and tozoloxamine are not effective antitoxins for respiratory depression due to overdosage or unusual sensitivity to Talwin, parenteral naloxone (Narcene, available through Endo Laboratories) is a specific and effective antagonist.

Talwin is not subject to narcotic controls.

How Supplied: Tablets, peach color, scored. Each tablet contains Talwin (brand of pentazocine) as hydrochloride equivalent to 50 mg. base. Bottles of 100.

© 1973 Winthrop Laboratories, New York, N.Y. 10016 

50mg. Tablets **Talwin®**
brand of
pentazocine
(as hydrochloride)
in moderate to severe pain

One Man...and Medicine

ARTHUR M. SACKLER, M.D.,
International Publisher, *Medical Tribune*



A Noble Man

WITH THE DEATH of Gustaf VI Adolf, Sweden lost a unique king and the world its oldest ruling sovereign.

Oscar Fredrik Wilhelm Olaf Gustaf Adolf was a man who was as unpretentious as he was beloved, as accomplished a botanist as he was an archaeologist, as great a linguist as he was an art connoisseur, as outstanding a scholar as he had been an athlete. His simplicity was offset by his remarkable perspective and humor. His sense of discipline and proportion was unusual in a man of his birth but consistent with his accomplishments and his talents. Once, in Venice for an exhibition of archaic jades, he expressed deep interest in a very fine piece. Upon learning its price, he amiably remarked, "A beautiful piece of coring, but too expensive for the poor King of Sweden."

Gustaf VI Adolf was a man of the world in the truest sense. He was a multinational genetic inheritance. He was the great-great-grandson of Jean Baptiste Bernadotte, one of Napoleon's generals, and son of a princess of the Grand Duchy of Baden in Germany. His first wife, Princess Margaret of Connaught, was a granddaughter of Queen Victoria of England, and his second wife, Lady Louise Alexandra Marie Irene Mountbatten, sister of Earl Mountbatten of Burma, was a great-granddaughter of Queen Victoria.

It was in 1963 when I had first received an invitation from Gustaf VI Adolf to attend the opening of the new Museum of Far Eastern Antiquities in Stockholm. My mother's terminal illness had necessitated a cancellation of that visit. Later, in Greece, when I was attending a medical congress, I saw him by chance in Athens, where he was attending the wedding of the Danish princess to the King of Greece. Some months ago I missed him after having made arrangements with Bo Gyllenswärd, Keeper of his collection, to meet in London with Gustaf VI Adolf and his personal physician, Gunnar Blorck.

Visited Him a Year Ago

About a year ago I visited the King's private apartment in the Royal Palace in Stockholm and shared that visit with you in this column. His apartment was one in which he had lived as a crown prince. He never moved after the simple ceremony which marked his "taking the throne." His personal unpretentiousness but deep and varied interests were reflected in each room. Despite the dimensions of the palace, one fell quickly "at home" in a dwelling which reflected the multiple interests of a scholar and archaeologist, a collector, and, above all, a world citizen.

Gustaf VI Adolf was no *courant* with modern archaeology and particularly interested in the fusion of the physical sciences with art history. He was fascinated by the x-rays of bronze, the use of carbon¹⁴ in the dating of organic materials, and the recently developed dating technique of thermoluminescence for ceramics. While he loved beautiful pots, lacquer, and bone carvings, he was particularly devoted to Chinese ritual bronzes and early jades.

Gustaf VI Adolf held honorary degrees from Princeton, Yale, Harvard, the University of Pennsylvania, Clark University, Lafayette College, and the University of Chicago and was probably one of the few men of royal lineage who had actually earned them. He enjoyed travel and spent much time in England. For many years he was unable, "for reasons of state," to visit the United States, which he would have particularly enjoyed because of his inter-

est in the great American collections of Chinese antiquities. Due to his age, his travel was restricted in terms of distance and climate. Supporters of the Swedish monarchy who were deeply concerned with its continuance believed the continuing reign of Gustaf VI Adolf vital for the transition to his grandson, now Carl XVI Gustaf, who at 27 is the youngest ruling monarch in Europe. In lieu of his personal visits, the King's collection of Chinese art and archaeology, representing 4,000 years of history, came to the United States and was exhibited at the National Gallery in Washington and Asia House in New York.

Interests Were Not Passive

Just as Gustaf VI Adolf was active in early life in athletics—on expert marksmen, a gifted horseman, a tennis player, and a skier—his scholarly interests were not a passive but a constant and growing personal participation. His studies in art history were supplemented by his work in field archaeology. While his greatest concentration had been on Etruscan digs, he previously had done field work in Sweden, Greece, Egypt, and China.

Gustaf VI Adolf's botanical work won him what was, for a monarch, a rare honor—membership in Britain's Royal Academy. His sensitivity to his role as a sovereign led him to forgo his rightful place among those scholars who did so much for our classification of Chinese bronzes and jades. He worked as collaborator but did not appear as coauthor.

I will never forget a fascinating incident which Bo Gyllenswärd, the King's curator, described to me. We had been discussing the King's interest in Chinese lacquer and the outstanding collection of a Chinese specialist in the field. This particular Chinese collector is renowned not only for his dedication, interest, and knowledge of this field but also for a passionate bluntness not usually associated with the so-called enigmatic and polite ways of the East. At one point in the discussion between the Swedish King and the Chinese connoisseur, the collector grasped Gustaf VI Adolf by the lapels of his jacket and with the greatest intensity exclaimed, "King, this is absolutely correct!" After he left, His Majesty turned to his curator and with his typically engaging smile said, "That was an unusual experience."

All who love art and its history, all who have admired the fruitful and stimulating contributions of Swedish science and the Nobel awards, all who appreciate scholarship and connoisseurship, and all who respect greatness with humility will miss that truly noble man, Gustaf VI Adolf.



I have often thought that the best way to define a man's character would be to seek out the particular mental or moral attitude in which, when it came upon him, he felt himself most deeply and intensely alive. At such moments there is a voice inside which speaks and says: "This is the real me!"

William James, M.D. (1842-1910)
writing to his wife

The Letters of William James

The Somatic Protest in duodenal ulcer

Excessive anxiety can exacerbate symptoms

Excessive emotional tension and anxiety are believed to cause adverse changes in the physiology of the stomach or the duodenum and thereby often contribute to the pathogenesis and aggravation of peptic ulcers.

Although the exact causative mechanism remains to be elucidated, gastric hypersecretion and intestinal hypermotility are, in many patients, end-organ manifestations, and these processes usually give rise to typical symptoms of duodenal ulcer.

Whenever immoderate, harmful anxiety is prominent in the clinical profile, consider—



Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of anxiety and tension occurring alone or accompanying various disease states.

Contraindications: Patients with known hypersensitivity to the drug.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. As with all

CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates,

have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.

Precautions: In the elderly and debilitated, and in children over six, initial or smallest effective dosage (initially 10 mg or less per day) to preclude elevation or overdose. Increasing gradually as needed and tolerated. Not recommended in children under six. Though generally not recommended, if combination therapy

with other psychotropics seems indicated, carefully consider individual pharmacologic effects, particularly in use of potentiating drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function. Pseudoloch reactions (e.g., excitement, stimulation and acutely rage) have been reported in psychiatric patients and hyperactive aggressive children. Employ usual precautions in treatment of anxiety states with

in addition to primary therapy—the adjunctive use of Librium to effect reduction of anxiety-linked gastrointestinal complaints or symptoms. Librium is used concomitantly with certain specific medications of other classes of drugs, e.g., anticholinergics and antacids.


Librium has an excellent record of effectiveness with safety.

After more than 13 years of wide clinical use, Librium continues to demonstrate its highly favorable therapeutic index. In general use, the most common side effects reported have been drowsiness, ataxia and confusion, particularly in the elderly and debilitated. When excessive anxiety has been reduced to appropriate, tolerable levels, therapy with Librium should be discontinued.

For relief of moderate to severe anxiety in duodenal ulcer patients

adjunctive **Librium® 10 mg**
(chlordiazepoxide HCl)

1 or 2 capsules t.i.d./q.i.d.



ROCHE
Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, N.J. 07110

evidence of impending depression; suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation have been reported very rarely. In patients receiving the drug and oral anticoagulants, causal relationship has not been established

Adverse Reactions: Drowsiness, dizziness and confusion may occur, especially in the elderly and debilitated. These are reversible in most instances by

proper dosage adjustment, but are also occasionally observed at the lower dosage ranges. In a few instances syncope has been reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, increased and decreased libido—all infrequent and generally controlled with dosage reduction; changes in EEG pattern (low-voltage fast activity)

may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts and liver function tests advisable during protracted therapy.

Supplied: Librium® Capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide HCl. Liblube® Tablets containing 5 mg, 10 mg or 25 mg chlordiazepoxide.

Institutionalized 98 Years—Reason Unknown



At the age of four, 98 years ago—yes, that is correct, 98 years ago—Martha Nelson was admitted to the Columbus State Institute for the Feeble Minded in Ohio. She was later transferred to the Orient State Institute where her records were destroyed by fire in 1933, so no one now knows why the 102-year-old woman was originally admitted. Dr. A. Z. Soforenko, superintendent of Orient, calls her quite coherent for her age. Martha has not been visited by anyone for about 20 years.



situation:
Elderly... doesn't get out much anymore... whole world slowed down... **constipation:**

Poor eating habits... often, on various constipating drugs... inactive, frequently debilitated... weakened muscles... sluggish, flaccid bowel. Result—In many oldsters—constipation.

laxation:

Gentle, predictable and easy-to-take SENOKOT Tablets or Granules. Taken at bedtime, they usually induce comfortable evacuation in the morning. Leave your older patient feeling more like getting up and around.

Supplied: SENOKOT Tablets (small, easy to swallow)—Bottles of 50 and 100. SENOKOT Granules (delicious, cocoa flavored)—4, 8 and 16 ounce (1 lb.) canisters.

Senokot

(standardized senna concentrate)
Tablets/Granules

a natural laxative

Purdue Frederick

© 1973, The Purdue Frederick Company, Inc., New York, NY 10016

Nerve Regeneration Speeded By Electromagnetic Energy

Medical Tribune Report

NEW YORK—The rate of regeneration of peripheral nerves in rats is significantly accelerated by exposure to pulsed electromagnetic energy, Dr. D. H. Wilson, consultant surgeon at the General Infirmary, Leeds, England, reported here.

In experiments described at the Conference on Electrically Mediated Growth Mechanisms in Living Systems, the median-ulnar nerve in the left forelimb of a series of pairs of rats was divided and sutured. Subsequently, one rat from each pair was treated daily by exposure to pulsed electromagnetic energy.

Healing time for surgical incisions was four days in the treated rats as compared with seven days in the control animals. Treated rats began to use their left forelimb after 10 days, untreated rats not until 21 days.

Nerve conduction studies at 12 days showed a modified response in the treated nerves but none in the untreated. At 30 days a biphasic action potential was demonstrated in the treated animals, and at 45 days their nerve conduction tracings were

indistinguishable from normal. Nerve conduction did not begin to return in the untreated nerves before 60 days.

Dissection of nerves for histologic studies revealed considerably less scarring and fibrosis around the nerve suture sites in the treated rats, suggesting that "there was also less fibrous tissue formed between the two halves of the nerve, thus permitting the more rapid recovery." Comparison of histologic preparations of nerves showed that treated nerves had recovered more fully at 30 days than untreated nerves had at 60 days.

Nerves Cleanly Divided

Regarding clinical applicability, Dr. Wilson cautioned that in his experiment the nerves were cleanly divided without complicating damage to surrounding tissues and were anastomosed within minutes. Furthermore, therapy was begun only two hours postoperatively, and comparable dosage for human beings would be impractically high. However, the experimental dosage was "quite empirical," and therefore "further experimentation may show that the same results can be obtained with a smaller dosage."

The nerve regeneration experiments grew out of a previous study comparing the effectiveness of conventional short-wave diathermy and pulsed electromagnetic energy in treatment of ankle sprains in human subjects. Results showed that in pairs of patients matched for sex, age, weight, and degree of trauma, short-wave diathermy produced a 44 per cent recession of symptoms in three days with a total energy transfer of 22 watt-hours, whereas only 15 watt-hours of pulsed electromagnetic energy therapy produced an 82 per cent recession of symptoms in the same period. "This finding throws very considerable doubt on the theory that using pulsed electromagnetic energy as a means of therapy is merely another method of generating heat in the tissues."

Domestic Meetings

Nov. 1 American Pancreatic Study Group, Chicago
Nov. 1-3 Association for Academic Surgery, Rochester, N.Y.
Nov. 1-3 Central Society for Clinical Research, Chicago
Nov. 1-3 Florida Medical Health Conference and Southeastern Industrial Health Conference, Tampa
Nov. 1-3 Southern Thoracic Surgical Association, Louisville, Ky.
Nov. 1-3 West Coast Allergy Society, Honolulu
Nov. 1-4 Pennsylvania Medical Society, Harrisburg
Nov. 2-4 Association of Clinical Scientists, Washington, D.C.
Nov. 2-4 National Laryngectomy Conference, Framingham, Mass.
Nov. 3 Conference of State and Provincial Health Authorities of North America, San Francisco
Nov. 3-7 American Urological Association, Dade City, Fla.
Nov. 4 Association for the Advancement of Psychiatry, New York
Nov. 4-6 American College of Obstetricians and Gynecologists, Honolulu
Nov. 4-6 American College of Preventive Medicine, San Francisco
Nov. 4-8 Association of American Medical Colleges, Washington, D.C.
Nov. 4-9 International and Civil Affairs Health Society, San Francisco
Nov. 5-7 Conference and Workshop on Embryonic and Fetal Antigen in Cancer, Kauai, Hawaii
Nov. 5-7 International Health Society of the United States, San Francisco
Nov. 5-7 Society of Military Orthopaedic Surgeons, El Paso, Tex.
Nov. 5-9 Gerontology Society, Miami Beach, Fla.
Nov. 6-10 American Society of Tropical Medicine and Hygiene, Houston, Tex.
Nov. 7-9 American Cancer Society, New York
Nov. 7-10 American Society of Women's Association, Palm Beach, Fla.
Nov. 7-10 American Society of Cytology, Salt Lake City
Nov. 7-10 Puerto Rico Medical Association, San Juan, P.R.
Nov. 8-10 American Social Health Association, New York
Nov. 8-15 American Association for Cancer Education, Honolulu
Nov. 8-13 American Heart Association, San Francisco

MEDICAL TRIBUNE has it first

cal Tribune

and Medical News

and its practice—fast, accurate, complete

Wednesday, September 5, 1973

New Cooper Procedure

Stimulator Over Cerebellum Controls Intractable Epilepsy



me Due ections s to 3-4

Field Service

—The 14 to 21 days exposure to rabies lost if a new rabies seed becomes available within two years. World Health Organization's rabies laboratory at Geneva, Switzerland, is to be reactivated in France, the United States and other American countries. The vaccine produced at Geneva is close to 100% effective. One dose administered to a person immunized with the vaccine has been sufficient to induce a protective level equal to 21 times the amount of rabies virus. The amount of rabies virus in a human being is not known.

Continued on Page 29

The x-ray shows the position of the electrodes placed in the surface of the cerebellum. The electrode is a thin wire, about 1/16 of an inch in diameter, which is inserted into the brain. The electrodes are placed in the cerebellum, which is the part of the brain that controls balance and coordination. The electrodes are placed in the cerebellum, which is the part of the brain that controls balance and coordination. The electrodes are placed in the cerebellum, which is the part of the brain that controls balance and coordination.

Continued on Page 29

Reduced Vitamin C

Nov. 1-3 American Society of Internal Medicine, New York
Nov. 1-3 American Society of Women's Association, Palm Beach, Fla.
Nov. 1-3 American Society of Cytology, Salt Lake City
Nov. 1-3 Puerto Rico Medical Association, San Juan, P.R.
Nov. 1-3 American Social Health Association, New York
Nov. 1-3 American Association for Cancer Education, Honolulu
Nov. 1-3 American Heart Association, San Francisco

Continued on Page 29

The time of life

Continued on Page 29

Newweek, October 1, 1973
Wednesday, September 5, 1973
Pacemaker for the Brain

MEDICINE

When he was 16, W.A. was struck on the side of the head by a baseball, four years later he began to suffer frequent and disabling epileptic seizures. As often as five times a day, feeling in his stomach, he would go into a convulsive attack and then go into a coma, often more frequent intervals suddenly lapsing into a brief, lucid state. Later, when the seizures became more frequent, he would fall into a coma for longer periods of time.

Powered transmitter that can be set of electrodes from the patient's body. In a cerebellum. But

JAMA
THE JOURNAL of the
American Medical Association
September 17, 1973 Vol 225, No 12

stimulation aids victims
hypertonia, epilepsy

THE NEW YORK TIMES, SATURDAY, SEPTEMBER 22, 1973
Pacemaker' Is Helping Some With Hypertonia

Continued on Page 29

The surgeon's latest innovation is a kind of brain "pacemaker" that, by delivering electrical impulses to the brain, can in some cases relieve the symptoms of hypertension. But it is still too early to know how long it will last and on which patients it will work.

Even if the pacemaker's results turn out to be short-lived, experts believe that

Continued on Page 29

The surgeon's latest innovation is a kind of brain "pacemaker" that, by delivering electrical impulses to the brain, can in some cases relieve the symptoms of hypertension. But it is still too early to know how long it will last and on which patients it will work.

Even if the pacemaker's results turn out to be short-lived, experts believe that

Continued on Page 29

The surgeon's latest innovation is a kind of brain "pacemaker" that, by delivering electrical impulses to the brain, can in some cases relieve the symptoms of hypertension. But it is still too early to know how long it will last and on which patients it will work.

Even if the pacemaker's results turn out to be short-lived, experts believe that

Gardening Provides Enjoyable Exercise For the Handicapped

Over the years, gardening has emerged as an increasingly popular aid in the rehabilitation of the mentally and/or physically handicapped person. In November, professionals in the field will meet for the first time to form the National Council for Therapy and Rehabilitation Through Horticulture. Howard Brooks and Charles Oppenheim, of New York University's Institute of Rehabilitation Medicine's greenhouse (shown here), have recently published a monograph on the subject, outlining many of their programs and techniques.



Metal spoons can be bent to help overcome physical deficiencies and problems, and other simple tools can also be adapted easily.



The work in the greenhouse offers not only exercise but also the experience of enjoying the warmth and beauty of flowers and plants. The experience raises the spirits of the patients and helps them to adjust to their handicaps.



Mr. Brooks (right) uses horticulture as one aspect of the patient's total program. Activities are based on goals established for the patient by his occupational or physical therapist.

Jamaica Study Finds No Harm In Chronic Use of Marijuana

Continued from page 1
and the results of in-hospital laboratory work, was submitted to HEW's National Institute of Mental Health in March, 1972, with no attendant publicity in this country.

In the clinical phase of the project, 30 confirmed smokers, in whom duration of regular use of marijuana ranged from seven to 37 years (mean of 17.5) were matched with 30 controls who either had never smoked or had never been regular smokers and had long ceased.

During a six-day period of abstinence from cannabis—while in University Hospital, Kingston, Jamaica—all 60 were assessed by detailed medical history and examination, heart and lung radiography, electrocardiography, respiratory function tests, blood chemistry, liver and renal function, hematologic studies and reproductive endocrinology, and chromosomal studies. In addition, blood and urine samples were analyzed for peripheral thyroid hormones, levels and steroid excretion.

None Had Used Herd Drugs

None of the 60 had ever used heroin, morphine, LSD, amphetamines, barbiturates, or Jimson weed. Of the 30 confirmed smokers, 27 also used tobacco. Of the 30 controls, 19 were tobacco smokers. Eight controls had had slight experience with marijuana.

The number of cigarettes (spiffs) that had been consumed per day at the time of the study ranged from one to 24, with an average of seven. Light use was defined as one to four spiffs a day, moderate use as four to seven, and heavy use as eight or more a day. Smokers who used the pipe consumed from one to 25 pipeloads per week, with an average weekly consumption of 14. Marijuana samples submitted for analysis by the smokers had a mean Δ-9 THC content of 2.96 per cent.

Possession or use of marijuana being illegal, it had been agreed that no studies of acute effects could be undertaken in University Hospital. Only one smoker is known to have breached the agreement—in a fit of dedication to science: "Haar me why I smoke it. Although you told me not to, I feel if a man is tested for a week and he doesn't smoke, it makes no sense. When a man tests me, I want him to find evidence that the smoke comes off me, and if it's effective it will show up. But if I stop smoking when I leave home to go to the theater, there's nothing left."

Blood pressures in both smokers and controls were within normal limits. Roentgenograms of the heart and lungs were normal in both groups, except for some scarring of the lungs in one of the controls. Smokers and controls were matched in height and in age, but the smokers were on average of seven pounds lighter, suggesting the possibility that habitual smoking causes some suppression of appetite.

No Abnormal Configurations

Abnormalities found in chromosomal studies of peripheral blood cultures were slightly more frequent in the nonsmoker controls. Chromatid breaks and gaps were seen in 2.36 per cent of cells of marijuana smokers and in 2.90 per cent of cells of controls—not statistically significant. No abnormal configurations, exchanges, or dicentrics were seen.

"It appears that chronic cannabis use has no significant effect on the mitotic chromosomes of human peripheral blood lymphocytes in the Jamaican man. The incidence of mild chromatid breakage was no higher than that found in random Jamaican subjects."

There were minor ECG abnormalities in 30 percent of both groups, perhaps indicating the prevalence of a cardiomyopathy that has been recognized in Jamaica, possibly attributable to an obliterative disease of the small coronary vessels, often associated with heavy tobacco consumption.

Hematologic studies revealed eosinophilia in 11 subjects, seven nonsmokers and four smokers—not statistically significant. No significant differences were

found in other hematologic tests, with the exception of hemoglobin and monocyte count values. There were twice as many nonsmokers as smokers in the low- (10-14 Gm./100 ml.) range. There were six smokers in the high (17-20 Gm./100 ml.) range; only one nonsmoker fell into this category. Twice as many smokers as nonsmokers had low (0.1 per cent) monocyte values; twice as many nonsmokers as smokers fell into the high (5.9 per cent) category.

Elevation of the liver enzymes, serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase, was found in seven subjects—three nonsmokers and four smokers—but did not indicate significant liver damage.

Several interesting trends were noted in respiratory function, indicating an association between frequency and duration of smoking per se (tobacco cigarettes, marijuana) with respiratory function and differences in blood chemistry. Chronic heavy smokers (more than 20 tobacco cigarettes per day, plus chronic marijuana smoking) are at greater risk of functional hypoxia. No other statistically significant differences were established.

Arterial blood determinations of oxygen, carbon dioxide, pH, bicarbonate, and pulse rate, at rest and immediately after exercise, were made. The only statistically significant difference between smokers and controls on these measurements was that bicarbonate after exercise was found to be lower among smokers.

The excretion of a number of urinary steroids in the chronic smokers and matched controls was studied for indications of marked changes in adrenal cortical function in the smokers. Smokers and controls were compared for urinary metabolites of cortisol. No differences were found between the two groups, either by t-test or by nonparametric statistical tests. The results indicated no significant reduction in cortisol secretion in the group of chronic cannabis users, compared with the nonsmokers.

Thyroxine Content Determined

Total thyroxine and free thyroxine content were determined. The groups did not differ from one another.

Comparative examinations of the 60 men were conducted by two members of the Department of Psychiatry, University of the West Indies, to whom they were randomly assigned.

The objectives were to seek evidence of psychoses, of abnormalities of mood, thought, behavior, or perception, that might be attributed to marijuana. Eysenck Personality Inventory (adult form) appraisals revealed no appreciable differences.

The ward staff, unaware of which subjects were smokers, observed that those who were in fact smokers were more affable and more popular. Men of the nonsmoking group were more often thought to be neurotic, and were more often impatient with ward routines and discipline.

No significant abnormalities emerged from mental status examinations. Only one subject, a nonsmoker, showed up as significantly depressed on the Hamilton Rating Scale. No score on either the Schizophrenic Rating Scale or the Wing Rating Scale was indicative of any disorder.

In view of the frequent reports that the use of cannabis leads to a near-do-well "motivational syndrome," particular attention was given to work records of the subjects. No significant differences were found between smokers and nonsmokers.

Electroencephalograms were obtained for all 60 subjects. No significant difference appeared between the two groups in definite abnormalities or equivocal cases. Further, most of the findings considered definitely abnormal or equivocal were focal in nature, unlikely to have been caused by any medication or drug effect.

Psychologic appraisals were done to see

Continued on page 36

The "Yes" Woman



Scanning electron microscopic view of section of bowel from patient with irritable bowel syndrome. Note multiple microconstrictions around openings of crypts. (6500X)

...whose irritable bowel syndrome says "no"

So compliant, sweet-tempered... always at the doctor's. For though she rarely complains, her insides do. She's a type commonly seen who can't express emotional tension except via the colon. Individual susceptibility, perhaps due to early experiences, may underlie such exaggerated responses to life stress.

Physical and psychological aspects

A functional disturbance, irritable bowel syndrome affects excretion, secretion and vascular functions—but most of all, tonicity—of the colon. Such dysfunction can result from emotional stress mediated by the autonomic nervous system. Thus the disorder can be expected to result from sustained anxiety in a susceptible individual. The patient needs reassurance and relief from emotional turmoil as well as relief from associated colonic spasm.

The dual nature of Librax

Librax is especially well suited to therapy for irritable bowel syndrome, for it combines in a single capsule the well-known antianxiety action of Librium® (chloridiazepoxide HCl) and the dependable antispasmodic action of

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Symptomatic relief of hypertension, hyperactivity and anxiety and tension states associated with organic or functional gastrointestinal disorders, and as adjunctive therapy in the management of peptic ulcer, gastritis, duodenitis, irritable bowel syndrome, spastic colitis, and mild ulcerative colitis.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering Librium (chloridiazepoxide hydrochloride) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of child-

bearing age requires that its potential benefits be weighed against its possible hazards. As with all anticholinergic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Overdosage: In elderly and debilitated, limit dosage to smallest effective amount to preclude development of ataxis and sedation.

Contraindications: Patients with glaucoma; prostatic hypertrophy and benign bladder neck obstruction; known hypersensitivity to chloridiazepoxide hydrochloride and/or chlordiazepoxide.

Warnings: Caution patients about possible combined effect with alcohol and other CNS depressants. As with all CNS-

stimulating drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical

Roche Image examines the concepts and discoveries that will shape tomorrow's medicine

Should they beget again?

*Unrecognized toxoplasmosis:
mimic extraordinary

Anesthesiology by laser

HMO's and the physician in the middle

**ROCHE
Image**
OF MEDICINE AND RESEARCH

*unrecognized
toxoplasmosis.*

beget again?...

Anesthesiology by laser.

next week in
Medical Tribune

Jamaica Study Finds No Harm In Chronic Use of Marijuana

Continued from page 34

whether there were any nonacute, lingering, or irreversible neuropsychologic effects in chronic smokers during the hospital period, when they abstained long enough to be physiologically free of the active chemical constituents of cannabis. (It is known that THC has a two-phase biologic half-life in which the rapid phase lasts about 30 minutes and the slow phase 56 hours. By the time the men were tested, there could have been very little, if any, THC in their bodies.)

The tests yielded no consistent differences between smokers and nonsmokers,

the data clearly indicating that long-term use by these men did not produce demonstrable intellectual or ability deficits when they were without the drug for three days. There was no evidence to suggest schizophrenic effects or brain damage.

In associated physiologic tests carried out in the field, independently of the hospital clinical studies, the work performance of farmers before, during, and after smoking of marijuana was closely observed by microanalysis of movements.

The director of the project for HEW was Vera Rubin, Ph.D., director of the Research Institute for the Study of Man, Lambros Comitas, Ph.D., Professor of Anthropology and Education, Teachers College, Columbia University, was codirector of this project.

The psychiatric testing was directed by Michael H. Beaubrun, M.B., Edin., FRCPsych., FACPysch., DFAPA, Professor of Psychiatry and head of the department, University of the West Indies. The nonpsychiatric clinical testing was directed by Eric K. Crichton, M.D., FRCP, Professor and Head of Medicine, University of the West Indies.

Hallucinations Not Reported

Questionnaires also revealed that hallucinations are not associated with smoking.

Only a few smokers reported having had visions of little male or female dancers, and then only under the influence of their first smoke—visions so stereotyped as to suggest that they were seen only because mythology says they are to be expected.

The director of the project for HEW

was Vera Rubin, Ph.D., director of the Research Institute for the Study of Man,

Lambros Comitas, Ph.D., Professor of Anthropology and Education, Teachers College, Columbia University, was codirector of this project.

The psychiatric testing was directed by

Michael H. Beaubrun, M.B., Edin.,

FRCPsych., FACPysch., DFAPA, Professor of Psychiatry and head of the department, University of the West Indies.

The nonpsychiatric clinical testing was directed by Eric K. Crichton, M.D.,

FRCP, Professor and Head of Medicine,

University of the West Indies.

Vitamin E Held Unsuccessful In Easing of Angina Pectoris

Continued from page 1

An additional part of the trial also demonstrated, they said, that discontinuance (on a double-blind basis) of previously prescribable vitamin E therapy did not result in a statistically significant difference in anginal symptoms between placebo and vitamin-treated patients.

The first part of the trial was the examination of data on 36 patients, recruited for the study by their attending physicians. Criteria for enrollment included a reasonably stable angina, no major change in health status or in usual medication for at least three months, and dependability—patients had to take test capsules regularly and keep adequate records.

Half of this group took a daily dose of 3,200 I.U. of vitamin E for nine weeks, while the remaining 18 took an indistinguishable placebo. The amount of vitamin E, as alpha-tocopherol succinate, was 10 times larger than that used in the only previous double-blind study.

Patients Paired Off

Patients were paired off as closely as possible by sex and age and were then assigned a code number from a computer-generated list of paired random numbers that had been used to number the vitamin and placebo containers.

The patients kept daily track of the number of nitroglycerin tablets taken each day during the trial. They also recorded whether anginal pain was worse, better, or the same as usual and whether physical activity was less, more, or the same.

Final assessments made by the attending physicians indicated that the majority of the patients in each group—13 on vitamin E and 12 on placebo—experienced no change in their angina. One patient on the vitamin regimen was assessed as "much improved" and four others as "improved." Among the placebo takers, none were "much improved" but three were "improved" and two were "slightly improved." One was "slightly worse."

Other reactions recorded by the two

groups also turned out to be quite similar. Most of the patients in each group showed little change in nitroglycerin consumption during the trial, and the majority in each group showed little change in activity score between the first and last weeks.

The net pain score for the placebo group was lower than that for the vitamin group in seven of the nine weeks, but if the last and the first weeks are compared, the over-all mean score dropped somewhat for the vitamin group and rose slightly for the placebo group.

In the second part of the trial, the investigators tested discontinuance of vitamin E therapy in seven of 15 patients who had been taking the vitamin for periods of months or years. (The same double-blind protocol was followed.)

This phase of the study yielded results that were more favorable to vitamin E therapy, the report stated. Four of the seven placebo patients experienced a worsening of original symptoms, compared with none of the eight who continued to receive regular doses.

The investigators noted, however, that this difference "was not statistically significant" and that the numbers of patients in the special trial were very small.

Also, such patients "may not have been as 'blind'" as those in the main trial, the report pointed out, since "it is conceivable" that patients accustomed to a large daily intake of vitamin E may experience the disappearance of some minor side effect, such as increased intestinal activity, and thus could be subconsciously alerted to the switch to placebo.

Discussing the failure of their double-blind trials to confirm the "dramatic effects" of vitamin E therapy claimed by other research teams, the Canadian Investigators suggested two possible explanations—vitamin E is really of no value, and previous successes can be attributed to a combination of spontaneous remission and placebo effect, or else the vitamin "has a small effect, and spontaneous remissions and placebo effects make up the balance."

The root of antihypertensive therapy



Serpasil® (reserpine)

Tablets, 0.25 mg (white, scored)

Tablets, 0.5 mg (white, scored)

Tablets, 1 mg (white, scored)

Tablets, 2 mg (white, scored)

Tablets, 5 mg (white, scored)

Tablets, 10 mg (white, scored)

Tablets, 25 mg (white, scored)

Tablets, 50 mg (white, scored)

Tablets, 100 mg (white, scored)

Tablets, 200 mg (white, scored)

Tablets, 400 mg (white, scored)

Tablets, 800 mg (white, scored)

Tablets, 1600 mg (white, scored)

Tablets, 3200 mg (white, scored)

Tablets, 6400 mg (white, scored)

Tablets, 12800 mg (white, scored)

Tablets, 25600 mg (white, scored)

Tablets, 51200 mg (white, scored)

Tablets, 102400 mg (white, scored)

Tablets, 204800 mg (white, scored)

Tablets, 409600 mg (white, scored)

Tablets, 819200 mg (white, scored)

Tablets, 1638400 mg (white, scored)

Tablets, 3276800 mg (white, scored)

Tablets, 6553600 mg (white, scored)

Tablets, 13107200 mg (white, scored)

Tablets, 26214400 mg (white, scored)

Tablets, 52428800 mg (white, scored)

Tablets, 104857600 mg (white, scored)

Tablets, 209715200 mg (white, scored)

Tablets, 419430400 mg (white, scored)

Tablets, 838860800 mg (white, scored)

Tablets, 1677721600 mg (white, scored)

Tablets, 3355443200 mg (white, scored)

Tablets, 6710886400 mg (white, scored)

Tablets, 13421772800 mg (white, scored)

Tablets, 26843545600 mg (white, scored)

Tablets, 53687091200 mg (white, scored)

Tablets, 107374182400 mg (white, scored)

Tablets, 214748364800 mg (white, scored)

Tablets, 429496729600 mg (white, scored)

Tablets, 858993459200 mg (white, scored)

Tablets, 1717986918400 mg (white, scored)

Tablets, 3435973836800 mg (white, scored)

Tablets, 6871947673600 mg (white, scored)

Tablets, 13743895347200 mg (white, scored)

Tablets, 27487790694400 mg (white, scored)

Tablets, 54975581388800 mg (white, scored)

Tablets, 109951162776000 mg (white, scored)

Tablets, 219902325552000 mg (white, scored)

Tablets, 439804651104000 mg (white, scored)

Tablets, 879609302208000 mg (white, scored)

Tablets, 1759218604416000 mg (white, scored)

Tablets, 3518437208832000 mg (white, scored)

Tablets, 7036874417664000 mg (white, scored)

Tablets, 14073748835328000 mg (white, scored)

Tablets, 28147497670656000 mg (white, scored)

Tablets, 56294995341312000 mg (white, scored)

Tablets, 112589990682624000 mg (white, scored)

Tablets, 225179981365248000 mg (white, scored)

Tablets, 450359962730496000 mg (white, scored)

Tablets, 900719925460992000 mg (white, scored)

Tablets, 1801439850921984000 mg (white, scored)

Tablets, 3602879701843968000 mg (white, scored)

Tablets, 7205759403687936000 mg (white, scored)

Tablets, 1441151880737584000 mg (white, scored)

Tablets, 2882303761475168000 mg (white, scored)

Tablets, 5764607522950336000 mg (white, scored)

Tablets, 11529215045900640000 mg (white, scored)

Tablets, 23058430091801280000 mg (white, scored)

Tablets, 46116860183602560000 mg (white, scored)

Tablets, 92233720367205120000 mg (white, scored)

Tablets, 184467440734410240000 mg (white, scored)

Tablets, 368934881468820480000 mg (white, scored)

Tablets, 737869762937640960000 mg (white, scored)

Tablets, 1475739525875281920000 mg (white, scored)

Tablets, 2951479051750563840000 mg (white, scored)

Tablets, 5902958103501127680000 mg (white, scored)

Tablets, 11805916207002255360000 mg (white, scored)

Tablets, 23611832414004510720000 mg (white, scored)

Tablets, 47223664828009021440000 mg (white, scored)

Tablets, 94447329656018042880000 mg (white, scored)

Tablets, 18889465931203608560000 mg (white, scored)

Table

